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Cardiovascular disease (CVD) is the leading cause of death in developed 
countries. Traditional cardiovascular risk factors account for only a fraction of events 
related to CVDs, emphasizing the need for investigations into more novel risk factors. 
Circulating angiogenic cells (CACs) are involved in the repair and maintenance of the 
vascular endothelium and function mainly through paracrine mechanisms. The studies 
presented in this dissertation provide new insight into differences in the paracrine actions 
of CACs as a function of habitual physical activity and CVD. The first study presented 
identifies, for the first time, that secreted factors from CD34+ and CD34-/CD31+ CACs 
affect HUVEC tube formation as a function of habitual physical activity. Study #1 
identifies inflammatory proteins S100A8 and S100A9 as major factors contributing to the 
depressed tube formation observed when using CD34-/CD31+ conditioned media (CM) 
from inactive younger adults compared to endurance-trained athletes. The second study 
aimed to confirm the effects of S100A8 and S100A9 in CD34-/CD31+ CM on HUVEC 
	  
tube formation in CVD patient populations compared to endurance-trained athletes. 
Study #2 found that the CM from non-ST- segment elevation myocardial infarction 
(NSTEMI) patient CD34-/CD31+ CACs impaired tube formation compared to athletes’ 
CM, and that pretreatment of HUVECs with an inhibitor for TLR4, a major receptor for 
S100A8 and S100A9, rescued tube formation to the levels observed when using CD34-
/CD31+ CM from athletes. Higher S100A8 and S100A9 content was found in the CM of 
NSTEMIs compared to athletes. Finally, the study #2 mechanistically demonstrated the 
direct role of S100A8 and S100A9 on tube formation using recombinant S100A8 and 
S100A9 and confirmed that these actions were mediated by TLR4. Preliminary data in 
study #2 suggest that cell surface markers on selected CD34-/CD31+ CACs are 
inherently different between NSTEMI patients and endurance-trained athletes with lower 
presence of T-cell and monocyte markers on the CD34-/CD31+ CACs of NSTEMI 
patients. Collectively, the two studies presented in this dissertation demonstrate that both 
physical inactivity and CVD alter the paracrine actions of CD34-/CD31+ CACs which in 
turn impair HUVEC tube formation. These findings are of particular importance as new 
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Chapter 1: Background and Specific Aims 
Background 
Cardiovascular disease (CVD) and the associated dysfunction of the vasculature is 
the leading cause of death in the developed countries (45). Studies suggest that the repair 
and maintenance of the vascular endothelium is critically dependent on the number and 
function of circulating angiogenic cells (CACs) (4, 147, 172). CAC is a broad term for 
subgroups of peripheral blood mononuclear cells with angiogenic properties that 
stimulate vascular repair and contribute to neovascularization. CD34 is the most 
commonly described cell surface marker on CACs that are known for their progenitor 
cell properties (103). CD31 is a cell surface marker most commonly found in mature 
endothelial cells, but has also been identified in circulating cells with angiogenic 
properties (75, 78, 86). Although not as commonly studied as CD34+ CACs for 
therapeutic neovascularization, CD31+ CACs have been found to exhibit similar 
angiogenic potential as CD34+ CACs in terms of improving mouse hind-limb ischemia, 
emphasizing the importance of studying non-progenitor cell lines which may also be 
involved in angiogenesis (78). Indeed, cells characterized by both markers have 
previously been found to exhibit angiogenic characteristics in vitro (4, 53, 75, 125) and in 
vivo (79, 95, 103).  
Originally believed to exert their reparative functions through direct incorporation 
into the endothelium (4), recent evidence indicates that CACs accomplish their pro-
angiogenic effects through paracrine mechanisms. Specifically, CACs are thought to 
secrete factors that elicit actions on the pre-existing endothelium and/or signal other 
circulating cells to home to the endothelium (79, 80, 125, 145, 175). Recently, Hynes et 
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al. (2011) demonstrated that the secretome from cultured CACs significantly reduced 
infarct area in a porcine model of myocardial infarction, suggesting that paracrine factors 
secreted by CACs may be more important for vascular repair than the cells alone (54). 
Urbich et al. found that CACs expressed and released a number of different factors that 
assist with the growth of mature endothelial cells to accelerate revascularization in 
ischemic tissues (145). This dissertation project will explore the susceptibility of CACs to 
modulation by physical inactivity or cardiovascular disease. 
Physical activity is associated with improvements in CV health, including 
attenuation of many classic CVD risk factors (65, 98) and improvements in endothelial 
function (22, 134). Our lab and others have previously shown that endurance exercise 
training increases CAC number and enhances intracellular redox balance in younger and 
older adults compared to their sedentary counterparts (63, 66, 94, 146, 147, 166). Hoetzer 
et al. (2007) found that migratory activity of sedentary individuals’ CACs improved by 
~50% after 12 weeks of exercise training (50). We previously documented that CACs 
from young sedentary but otherwise healthy individuals exhibit an unfavorable balance 
between reactive oxygen species (ROS) and nitric oxide (NO) compared to their 
endurance-trained counterparts (63, 66). It is generally accepted that CACs from older 
individuals with CVD exhibit less than optimal function and consequently, cannot 
contribute properly to vascular repair or neoangiogenesis (35).  
Previous studies have examined the effects of endurance exercise habits on CAC 
function through measures such as migration and adhesion (50, 148), but the effects of 
physical activity or disease on the paracrine function of CD34+ and CD31+ CACs are 
less explored. Additionally, the roles of factors secreted from CACs on angiogenesis are 
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not well understood. As such, the purpose of this dissertation is to identify how physical 
inactivity and cardiovascular disease can affect the paracrine function of CACs and their 
impact on endothelial tube formation. Therefore, the overall aim of this dissertation 
work is to identify key factors secreted by CACs affecting angiogenesis that may be 
differentially secreted as a function of physical activity status or cardiovascular 
disease. Initial investigations assessed the effect of chronic endurance exercise habits on 
the CAC paracrine factors and how this influences angiogenic tube formation. We also 
identified secreted factors present in the conditioned medium (CM) of two CAC subtypes 
and determined whether two identified proteins of interest were differentially secreted as 
a function of exercise training status. The purpose of this dissertation was to determine 
the role of the secreted factors from CVD patients’ CACs on angiogenic tube formation 
and to mechanistically determine whether certain proteins are contributing to the 
dysfunctional CAC properties observed in CVD patients. 
 
Specific Aim #1: To determine whether there is a differential response of paracrine 
effects of CD34+ and CD34-/CD31+ CACs on angiogenic tube formation as a result of 
chronic endurance exercise habits in younger men and women. 
The purpose of this study was to determine whether there is a differential 
response in paracrine effects of CD34+ and CD34-/CD31+ CACs on angiogenic tube 
formation as a result of chronic endurance exercise habits in younger men and women. 
Additionally, we aimed to identify differences in CAC intracellular redox pathways that 
may be eliciting angiogenic or anti-angiogenic actions. In this study we demonstrated that 
conditioned media (CM) generated from inactive subjects’ CD34+ and CD34-/CD31+ 
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CACs depressed human umbilical vein endothelial cell (HUVEC) tube-formation. 
Furthermore, there appears to be a graded response as a function of habitual exercise 
levels with CM from inactive individuals contributing to lower HUVEC tube formation 
compared to their active and endurance-trained counterparts. These data strongly suggest 
that endurance exercise training-mediated alterations in CAC paracrine activity influence 
angiogenesis. Other studies have demonstrated the role of paracrine signaling of CACs in 
disease states (54, 125, 174), but our data provide further support for a paracrine role for 
CD34+ and CD34-/CD31+ CACs on angiogenesis in younger, healthy individuals. 
Importantly, to our knowledge, this is the first report of a differential paracrine role in 
CD34+ and CD34-/CD31+ CACs on HUVEC-based tube formation as a function of 
chronic physical activity habits. These data emphasize the negative impact that a 
sedentary lifestyle can have on cellular biological processes even in younger, otherwise 
healthy adults before other, classic risk factors for CVD are present. As previous research 
in our lab would support (63), we hypothesized that differences in intracellular ROS and 
NO concentrations as a result of exercise-training status may, at least partially, explain 
the observed differences in paracrine function in both cells types. Surprisingly, our data 
suggest that intracellular ROS and NO may not play a major role in regulating the 
differential paracrine responses observed. There were no significant effects of training 
status on intracellular NO or ROS levels or in mRNA expression for eNOS as well as 
p47phox and gp91phox for either cell type. As such, we began investigating potential 
differences in secreted factors as a function of exercise training status that may contribute 
to the differential effects of tube formation caused by CAC conditioned media. Specific 
aims #2 and #3 of this dissertation focus on the identification of novel proteins secreted 
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by CACs and the effects of habitual physical activity and CVD on the secretion of these 
proteins. 
 
Specific Aim #2: To identify proteins present in the CM of CD34+ and CD34-/CD31+ 
CACs and to determine whether these proteins are differentially expressed as a function 
of chronic exercise training status. 
In an attempt to further investigate potential contributors to our observed 
differences in tube formation, we used mass spectrometry and identified two members of 
the S100 family of calcium-modulated proteins, S100A8 and S100A9, in the secretome 
of both CD34+ and CD34-/CD31+ CACs. S100A8 and S100A9 proteins are abundantly 
expressed in both myeloid and vascular cells (5) and are most commonly known for their 
role in regulating inflammatory processes. These proteins can function independently as 
homodimers or as a S100A8/A9 heterodimer complex. Several studies have linked 
systemic concentrations of the S100A8/A9 heterodimer complex to CVDs (5) with higher 
plasma levels predicting future CV events in middle-aged healthy individuals (17, 18). As 
S100A8 and S100A9 have established ties to CVD and inflammation, we decided to 
focus the investigations for aims 2 and 3 on the role of these proteins in angiogenesis. 
Upon identification of these proteins in the conditioned media of both CD34+ and CD34-
/CD31+ CACs, we confirmed that both CAC sub-types expressed the mRNA for both of 
these proteins, although no differences in mRNA expression were found as a function of 
physical activity habits. As our observed differences in tube formation appeared to be a 
graded effect, we focused on the two extreme groups, endurance-trained and inactive, for 
protein analyses in the conditioned media. The purpose of this investigation was to 
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determine if levels of S100A8 and S100A9 in CD34+ and CD34-/CD31+ conditioned 
media were differentially expressed as a function of chronic exercise training status. In 
this study, we did not observe an effect of training status on S100A8 or S100A9 protein 
expression in CD34+ CM that might explain the differences in CM-induced 
angiogenesis. However, we found that there was a 103% more S100A9 content in the 
CD34-/CD31+ CACs from inactive subjects compared to their endurance-trained 
counterparts. These findings are the first, to our knowledge, to demonstrate differential 
secretion of S100A9 by CD34-/CD31+ CACs as a function of an individual’s exercise-
training status. Although not statistically significant, S100A8 content was approximately 
twice as high in the CD34-/CD31+ CM from inactive subjects compared to endurance-
trained subjects. Given the biology of the S100A8/A9 complex, it is possible that the 
S100A8 findings in CD34-/CD31+ CM paired with the significant differences in S100A9 
may be physiologically relevant. However, future studies assessing the impact of the 
complex as a whole and functions of different proportions of S100A8 to S100A9 are 
necessary to confirm these speculations. These results suggest that increased 
concentrations of S100A8 and S100A9 secreted by CD34-/CD31+ CACs may contribute 
to lower tube-formation in inactive individuals. 
In an effort to estimate approximately how much of each protein was in the CM to 
which the HUVECs were exposed to in specific aim #1, we used recombinant human 
S100A8/S100A9 and created a standard curve using known concentrations found in the 
literature and compared those to the concentrations found in a subset of samples from this 
study. We found that the CM from both cell types contained substantially less S100A8 
and S100A9 than other investigations assessing the in vitro effects of these proteins (5, 
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92, 151). Thus, CM content in this study is on the low end of the established in vitro 
range of S100A8 or S100A9 concentrations. Defining the concentrations of S100A8 or 
A9 is important since previous publications have shown concentration dependent effects 
on angiogenic function (92, 151). In addition, both proteins are able to activate signaling 
in a homodimer, heterodimer or heterotetramer form (152), thus adding more complexity 
to their mechanism of action. Importantly, when the ratio of S100A8/S100A9 was 
calculated in the CM there was a greater proportion of S100A8 to S100A9 in the CD34-
/CD31+ CM compared to that of the CD34+ CM (2.343 vs. 0.513, respectively). These 
results suggest that CM from the different cell types are fundamentally different from one 
another even though both showed similar effects on the HUVEC tube formation. The 
differences in the ratios of these proteins in the CM of the two different cell types may 
provide one explanation for the observed differences in these proteins as a function of 
training status in the CD34-/CD31+ CM but not in the CD34+ CM. This also suggests 
that other secreted factors may also be participating in the observed differences in CD34+ 
CM-mediated HUVEC tube formation as a function of training status. 
To confirm the direct effects of S100A8 and S100A9 on HUVEC tube formation, 
the concentrations and proportions estimated in the CM of the inactive subjects’ CD34-
/CD31+ CACs were used in an angiogenesis assay. As estimated, 7.18 µg/mL of 
recombinant human S100A8 (ProSpec Bio) and 3.06 µg/mL of recombinant human 
S100A9 (Life Technologies) were added to a HUVEC-based tube-like formation assay 
and compared to the positive control prepared with EBM-2 and vehicle control. In these 
experiments, each condition was assessed in samples collected from six independent cell 
culture wells from multiple culture plates collected on different days and on cells from 
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the same passage number. Compared to the basal control, addition of S100A8 and 
S100A9 resulted in an average of 18% lower tube length and 28% lower complexity. 
These data indicate the direct effects of S100A8 and S100A9 on HUVEC tube-formation 
and support our earlier findings suggesting that differences in S100A8/A9 present in the 
CM may be responsible for the differential tube formation observed as a function of 
exercise-training status. 
Based on the results of specific aims #1 and #2, we concluded that a) there is a 
differential paracrine role of CD34+ and CD34-/CD31+ CACs on HUVEC-based tube 
formation as a function of chronic physical activity habits, b) pro-inflammatory S100A8 
and S100A9 secreted by CD34-/CD31+ CACs is twice as high in the CM of inactive 
individuals compared to their endurance-trained counterparts, and that c) recombinant 
S100A8 and S100A9 added in concentrations estimated to be present in the CM of 
inactive CD34-/CD31+ CAC significantly reduce HUVEC tube-formation. To 
summarize the dissertation work completed thus far, increases in secreted pro-
inflammatory factors S100A8 and S100A9 in inactive individuals appear to contribute to 
the reduced HUVEC tube-formation associated with CM from CD34-/CD31+ CACs. If a 
sedentary lifestyle promotes secretion of inflammatory factors, one would assume that 
this effect would then be exacerbated with age and progression of CVD. As such, the 
final aim of this dissertation will focus on studying the paracrine effects of CACs from 
CVD patients. 
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Specific Aim #3: To determine if inhibition of S100A8/A9 receptors will improve the 
depressed tube formation of HUVECs cultured with CD31+ CM from CVD patients 
compared to endurance-trained individuals.  
Recently, various sub-fractions of CACs have been used in autologous intra-
coronary cell transplants in attempt to to treat ischemic CVD and improve vascularization 
in humans (95, 120). Losordo et al. reported decreased angina frequency and improved 
exercise tolerance in patients with refractory angina in a clinical trial in which purified 
autologous CACs were injected into the injured area (95). While promising, the broader 
spectra of clinical trials in this area have reported only moderate success. As mentioned 
earlier, it is well established that individuals with CVD have fewer numbers and lower 
functioning CACs than healthy individuals (35, 44, 142). Thus, some of the variability in 
the literature can potentially be attributed to the autologous nature of the cell transplants, 
in which presumably lower functioning cells from a diseased patient are used to treat the 
same patient. This would hamper the use of CACs for autologous treatment in CVD 
patients, who are in the greatest need for such therapies. As such, it is critical to 
understand more about how CACs from CVD patients function and what tools we can 
use to improve their function to enhance the therapeutic use of these cells. As both the 
literature (79, 126) and our lab (87) have demonstrated the importance of CAC paracrine 
actions on endothelial cells, the focus of this final dissertation project will be on 
understanding the paracrine role of CACs from CVD patients. 
 
Hypothesis I: Culture of HUVECs with CM from CD34-/CD31+ CACs of CVD patients 
will result in lower HUVEC tube formation compared to endurance-trained subjects and 
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this will be associated with higher levels of S100A8 and S100A9 in the CD34-/CD31+ 
CM of CVD patients. 
This hypothesis was tested by isolating and culturing CD34-/CD31+ CACs from 
CVD patients and endurance-trained subjects to allow for secreted factors to be released 
into the culture medium. CM derived from cultured CACs will then be used in a 
HUVEC-based tube formation assay as we have done previously in specific aim #1 to 
determine if secreted factors from CACs of each group will contribute to a differential 
endothelial tube formation. Endothelial tube formation with the commonly used HUVEC 
line is a well accepted functional assay and the use of cell-free CM will enable the 
measure the effects of secreted factors from CD34-/CD31+ CACs of CVD patients 
compared to a model of optimal CAC function, endurance-trained subjects. A proteomics 
approach on a subset of samples from each group is proposed to confirm our previous 
findings and to identify other potential proteins in the CD34-/CD31+ CM that are 
differentially present or expressed between CVD patients and younger endurance 
athletes. Additionally, as our earlier studies indicate, S100A8 and S100A9 are likely 
candidates to explain the lower tube formation hypothesized for the CVD patients’ 
CD34-/CD31+ CM. Thus, Western blots examining the differences in levels of these 
proteins in the conditioned media of CD34-/CD31+ CACs from each subject group will 
be used as was done in specific aim #2.  
By investigating the pro-inflammatory S100A8 and S100A9 proteins in specific 
aim #2 we have focused on potential factors that may contribute to the dysfunction in 
CACs of younger, inactive adults as a means of identifying potential early risk factors for 
the development of endothelial dysfunction and CVD. A sedentary lifestyle is associated 
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with future CVD risk independently and through diseases such as obesity and Type II 
Diabetes, and it is possible that differences in the secretion of these proteins in sedentary 
but otherwise young and healthy individuals will become more exacerbated with age and 
progression of CVD in the absence of lifestyle changes. As such, our previous findings, if 
used as a predictor of future CVD risk, might be extrapolated to explain some of the 
dysfunctional properties of CACs from CVD patients.  
As mentioned, S100A8 and S100A9 plasma concentrations positively correlate 
with CVD risk (17). Thus, the presence of these proteins in our CM indicates a potential 
role of CAC paracrine factors in the pathological setting of cardiovascular disease. 
However, the direct effects of secreted S100A8 and S100A9 on the endothelial 
microenvironment is still not completely understood. Investigations into these pathways 
and the mechanisms through which S100A8/A9 secreted by CACs function in CVD 
patients are important issues for future research in this area. As such, the next purpose 
within specific aim #3 is to mechanistically determine how S100A8 and S100A9 secreted 
by CD34-/CD31+ CACs from CVD patients are contributing to depressed endothelial 
tube formation. The importance of studying CVD patients, the same individuals who are, 
in theory, candidates for such autologous CAC treatments, is clear. Additionally, 
comparing them to endurance trained athletes is a practical step based on the findings of 
our lab indicating these individuals serve as a model for optimal CAC function. A 
number of recent studies have begun to focus on therapies to enhance the function of 
CACs (13, 70, 89). The results of many of these studies are promising in both in vitro and 
in vivo animal models (13, 58). However, what “improved” function means for relevant 
physiological and clinical outcomes is yet to be determined. Our lab has shown that 
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CACs from endurance-trained younger and older athletes are of higher number and 
function compared to their sedentary peers (63, 87, 166). We have previously found that 
CACs from young sedentary but otherwise healthy individuals exhibit an unfavorable 
intracellular redox balance compared to endurance-trained individuals (63). In addition, 
results from many other laboratories support the role of aerobic exercise in enhancing the 
function of CACs (63, 94, 146-148). As such, we believe in using young, endurance-
trained athletes as a model of “optimal” CAC function as a comparison and ultimate goal 
when treating CACs to enhance their function prior to cell therapy. 
 
Hypothesis II: Inhibition of receptors for S100A8 and S100A9 on HUVECs will prevent 
S100A8 and S100A9 from binding and consequently rescue HUVEC tube formation 
when cultured with CM from CVD patients to levels similar to those observed when 
HUVECs are cultured with CM from endurance-trained subjects. 
Research investigating the role of S100A8 and S100A9 in CVD has found that 
these proteins can affect endothelial function in a number of ways. In vivo, it has been 
found that S100A8/A9 are involved in leukocyte recruitment during the response to 
vascular injury, promoting atherosclerotic lesions (18). In vitro studies have found that 
these proteins can decrease endothelial monolayer integrity (151, 162), and increase 
adhesion molecules and other pro-inflammatory factors on HUVEC cells (151). 
However, the effects of these proteins in the concentrations secreted by CACs of 
individuals of different health and disease statuses are still not completely understood. As 
such, the final aim of this dissertation is designed to mechanistically alter the ability of 
S100A8 and S100A9 present in the CD34-/CD31+ CM of our CVD patients and 
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endurance athletes to bind to and act on HUVEC cells and to assess the level of HUVEC 
tube formation under these conditions.  
Two major well-known receptors for S100A8/A9 are the receptor for advanced 
glycation end products (RAGE) (11)and Toll-like receptor-4 (TLR4) (26, 155), with 
S100A8 having a preference for TLR4 and S100A9 preferring RAGE (162). When the 
S100A8 and S100A9 proteins bind to RAGE and TLR4, they modulate calcium signaling 
and cytoskeletal reorganization (18, 48, 154) through p38 and ERK1/2 signal pathways 
downstream of these receptors (162). One investigation into these signaling pathways in 
HUVEC cells found that S100A8/A9 caused endothelial barrier dysfunction increasing 
HUVEC monolayer permeability through RAGE and TLR4/p38/ERK1/2 signaling (162). 
We are interested in the effects of the levels and proportions of S100A8 and S100A9 
present in the secretome of CD34-/CD31+ CACs of patients with CVD on HUVEC-
based angiogenic tube formation compared to those present in the secretome of 
endurance trained individual’s CACs. Using an antagonist for RAGE and TLR4 signaling 
inhibitor both individually and in combination to prevent the downstream effects of 
S100A8/A9 binding, HUVECs will be pre-treated before use in the tube formation assay 
to determine how inhibition of these receptors and thus, the ability of these proteins to 
bind to and act on HUVECs through their major receptors will affect the tube formation 
capacity. It is expected that tube formation using the CM from CVD patients will result in 
lower HUVEC tube formation and that pretreatment with these receptor antagonists will 
allow tube formation to be restored to a level similar to that observed when using CM 
from endurance-trained athletes.  
As the differences in levels of S100A8 and S100A9 as a function of training 
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status in specific aim #2 were observed only in CD34-/CD31+ CACs, specific aim #3 
will focus on the differences in S100A8 and S100A9 in the conditioned media of just 
CD34-/CD31+ CACs. CD34-/CD31+ CACs have been found to exhibit similar 
angiogenic potential as the more commonly studied progenitor-type CACs in terms of 
improving mouse hind-limb ischemia (78).  Indeed, cells characterized by this marker 
have been previously found to exhibit angiogenic characteristics both in vitro (75, 84) 
and in vivo (79). Given the proven angiogenic capacity of this cell type, coupled with the 
results of specific aim #2, we have decided to focus on this one cell type for the final aim 
of this dissertation work. Additionally, there are significantly more CD34-/CD31+ CACs 
present in peripheral blood compared to CD34+ CACs, which have even more reduced 
circulating numbers in individuals with CVD (35, 103). As such, a more mechanistic 
project can be completed using the CD34-/CD31+ CAC subtype due to their greater 
numbers, and perhaps more biologically significant in terms of their paracrine functions 
and effects on angiogenesis based on the earlier findings in specific aim #1 and #2. 
 
Exploratory Hypothesis: S100A8 and S100A9 present in the CD34-/CD31+ CM of 
CVD patients act through p38/ERK/NFκB signaling pathways of endothelial cells and 
inhibition of the receptors for these proteins on HUVECs will reduce expression of these 
proteins. 
Protein detection in frozen CM has been done successfully in our lab in the past 
(87). However, frozen CM in has not been found viable in cell culture experiments in our 
hands. As such, in an effort to collect additional data for future experiments in which we 
begin to explore the signaling pathways through which S100A8/A9 are acting on the 
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HUVEC cells, we plan to use fresh CM to perform cell culture experiments as an 
exploratory aim. Literature indicates that S100A8 and S100A9 act through TLR4 and 
RAGE and signal downstream MAP kinases that increase endothelial cell permeability 
and cytoskeletal structure of HUVECs (18, 162). This exploratory aim will examine 
whether effects of the CVD patient’s CD34-/CD31+ CM may also be occurring through 
this same pathway to reduce HUVEC function. The expression of different proteins 
downstream of each receptor on HUVEC cells exposed to CM from each subject 
population with or without HUVEC pretreatment with a RAGE antagonist and/or TLR4 
inhibitor will be examined. Phosphorylation of the MAP kinases, p38 and ERK1/2, and 
expression of NFκB using western blot to determine if a) conditioned media from CVD 
patients up-regulates expression of each of these proteins to a greater degree compared to 
endurance-trained subjects, and b) pretreatment of HUVECs with a RAGE antagonist 
and/or TLR4 inhibitor will down-regulate expression of p38, ERK1/2, and NFκB to 
levels closer to those expected with HUVEC exposure to endurance-trained subjects’ 
CD34-/CD31+ CM are proposed to be measured.  
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Figure 1.1 Downstream signaling for two major receptors for S100A8/A9 and proposed 
targets of measurement for exploratory aim to assess potential signaling pathways 
involved in HUVEC dysfunction when exposed to factors secreted from CVD patients’ 
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Chapter 2: Review of Literature 
The purpose of this literature review is to examine the research investigating circulating 
angiogenic cell function, specifically regarding paracrine actions of CACs, and the role 
that exercise and cardiovascular disease play in modifying these functions. 
 
Cardiovascular Disease and Endothelial Dysfunction 
Cardiovascular disease (CVD) is the leading cause of death in developed 
countries around the world (45). It is estimated that by 2030, over 40% of the US 
population will have some form of CVD with direct medical costs tripling as a result 
(45). Advancing age, physical inactivity, obesity, dyslipidemia, diabetes, hypertension 
and smoking are just some of the traditional risk factors involved in the development of 
CVD. Each of these factors, independently or coupled with others, contributes to 
impaired endothelial function, which is one of the first steps in the development of CVD 
and often precedes clinical cardiac events (22, 134). Over time, an imbalance occurs 
between inflammatory, oxidative stress, and vasodilatory factors that leads to vascular 
endothelial dysfunction, which then contributes to the increased risk of developing CVD 
(134) (Figure 2.1). However, traditional CV risk factors, such as those listed above, 
explain only ~50% of CVD events, (12, 112) providing a need to investigate other novel 















Figure 2.1 Progression of atherosclerosis over time and associated endothelial 
dysfunction (119) 
 
History of Circulating Angiogenic Cells and Early Studies 
In 1997, Asahara and colleagues first isolated putative endothelial progenitor cells 
(EPCs) from human blood using immunomagnetic separation methods (4). These cells 
were able to differentiate into mature endothelial cells in vitro and also were incorporated 
into sites of vascular damage in an in vivo animal model of hind limb ischemia (4).  This 
was the first demonstration of the efficacy of adult circulating cells with angiogenic 
potential as a potential therapy for treating CVD and, since then, a vast amount of 
research has studied circulating cells that can aid in therapeutic angiogenesis. Asahara et 
al., (1997) used two cell surface markers, CD34+ and vascular endothelial growth factor 
receptor 2 (VEGFR2+ or KDR+) to identify these angiogenic cells, due to the presence of 
these markers on early hematopoietic cells and mature endothelial cells but not 
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differentiated hematopoietic cells (4). Since this study was published, the field of “EPCs” 
has grown and the definition of a true EPC has become widely debated (171). This has 
lead to the identification of a number of other circulating cell types that do not fit the 
strict definition of EPC (29, 171). Thus, the term circulating angiogenic cell (CAC) has 
been adopted as a global term to represent all cell types found in the circulation or 
cultured from circulating cells that have angiogenic properties that are associated with 
endothelial repair and maintenance.  
Identification of Endothelial Progenitor Cells Versus CACs 
 EPCs are generally characterized as “early” EPCs (eEPCs) and “late” or 
“outgrowth” EPCs (OEC). Both can be derived from culturing human peripheral blood 
mononuclear cells (PBMCs) on fibronectin or gelatin after removal of nonadherent cells 
on day 2. Early EPCs appear after 4-10 days of culture and express CD45 and typical 
myeloid markers, such as CD14. They have been found to have high paracrine activity, 
and some have found that they can incorporate into capillaries (29, 53, 69, 149). Using 
the same culture conditions as described above, OEC generally appear after two or more 
weeks of culture and have been found to be molecularly distinct from eEPCs (108). 
OECs exhibit lower paracrine activity and incorporate well into capillaries (29, 53, 69, 
149). Although both types of EPCs have been associated with functional improvements 
in the treatment of hindlimb ischemia and acute myocardial infarction, the molecular 
phenotype of eEPCs is more closely linked to monocytes while OECs are more 
committed to an endothelial lineage (108). 
 Others have found that culturing PBMCs on collagen for 2-3 weeks results in a 
cell type that is believed to be the “true” EPC because they lack CD45 and CD14 and 
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most closely resemble endothelial cells (57, 171). These cells, termed endothelial colony-
forming cells (ECFCs), have high proliferation capacity and exhibit in vivo vessel growth 
on matrigel. However, these cells lack the progenitor cell marker and some speculate that 
they may be either derived from the vascular wall rather than bone marrow or a product 
of their culture environment as these “true” EPCs are not detected in circulation (29, 53). 
 Hill et al. developed another method of identifying “EPCs” through culture of the 
non-adherent cells after PBMCs were cultured for 48 hrs. Using this method, colony-
forming units (CFU-ECs) appear around 5 days and are comprised of a heterogenic 
population of cells including cells with progenitor, endothelial, myeloid and T-cell 
markers (29, 35). Due to the heterogenic nature of CFU-ECs and their similarity to 
monocytes, it has been generally agreed that these cells should not be regarded as EPCs, 











Figure 2.2 Association between CAC number, endothelial dysfunction and 
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Circulating Angiogenic Cells  
Direct comparison of results from various studies has proven difficult due to the 
different classifications and culture conditions for “EPCs”. As no single cell marker to 
date has been unanimously accepted as identifying “true” EPCs, many of these cells, 
including the CFU-ECs, eEPCs, and cells isolated by single or multiple cell markers are 
now being classified under the umbrella term CAC. As a whole, it is generally accepted 
that CACs are involved in the repair and maintenance of the vascular endothelium, with 
the number and function of certain CACs being inversely related to CVD risk (7, 8, 46) 
(Figure 2.2).  
Selection of cells using a single or multiple cell surface antigens has been used to 
enrich culture environments (4, 126) in order to study the function and properties of 
specific purified cell populations freshly isolated from peripheral blood from humans of 
different health statuses or in response to an intervention (63, 95, 165). Some of the more 
commonly studied cell markers include CD34+, CD133+, VEGFR2+ and CD31+. As all 
of the above listed cell types have been found to exhibit angiogenic properties (29, 35, 
75, 78, 79, 95, 103), for purposes of this review, the broad term CAC will be used with 
specific cell markers listed where appropriate. 
CAC Isolation by Single Marker 
CD34+ CACs 
CD34 is the most commonly described cell surface marker on CACs that are 
known for their progenitor cell properties (103). This cell type rose in popularity as a 
circulating cell with angiogenic potential due to the presence of the CD34 antigen on both 
progenitor cells and fully differentiated vascular endothelial cells (103). As such, it was 
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believed that these circulating cells could adopt an endothelial phenotype and contribute 
to the development of new blood vessels in response to ischemic damage resulting from 
an acute CV event (95, 103). Although the complete cellular functions of the CD34 
protein are not completely understood, there is support for its role in promoting 
proliferation of hematopoietic progenitor cells from both the blood and bone marrow 
(16). The basal density of CD34+ cells in circulation without the use of mobilizing agents 
is relatively low (~1% of total mononuclear cells (MNCs), with advanced age and 
chronic CVD contributing to a decrease in both number and functional properties of these 
cells (103).  
 Although CD34 is arguably the most commonly studied cell surface marker, it is 
usually studied in combination with endothelial markers (i.e. VEGFR2+) and/or other 
progenitor cell markers (CD133+). There have been, however, a few groups who have 
investigated CD34+ through immunomagnetic isolation of just the single marker. In 
2006, Kawamoto et al. provided one of the first examples of purified mobilized human 
peripheral blood CD34+ cells as an effective treatment for myocardial ischemia 
compared to total MNCs (72). They found that treatment with CD34+ CACs improved 
capillary density, reduced percent fibrosis, and better preserved echocardiogram regional 
wall motion score compared to treatment with high and low doses of MNCs in rats after 
experimental myocardial infarction (MI) (72). Other studies found that CD34+ CACs 
were more effective in healing and improving vessel growth after hindlimb ischemia in 
mice compared to CD14+ monocytes (6). Due to some promising results in these earlier 
animal studies, autologous cell transplants have been tested in human clinical trials for 
various ischemic diseases. A Phase I/II randomized double-blinded trial published in 
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2007 provided evidence for the safety and feasibility of autologous CD34+ cell therapy 
for treatment of angina (97). Subsequent clinical trials by the same lab examined the 
bioactivity of these autologous cell therapies in patients with refractory angina and found 
improvements in angina frequency and exercise tolerance (95) with a phase III clinical 
trial currently underway (106).  
Further pre-clinical trials in Lorsordo’s lab have also begun exploring the 
feasibility for autologous intramuscular transplantation of CD34+ cells for the treatment 
of individuals with critical limb ischemia. An initial randomized placebo controlled pilot 
study found favorable results with lower amputation rates (22% versus 75% of controls) 
in the CD34+ CAC treated group with critical limb ischemia one-year post treatment 
(96). Later phase II clinical trials found improvements in a number of physiological 
parameters including skin perfusion pressure, pain free walking distance and 
transcutaneous partial oxygen pressure in patients just 1-2 weeks after treatment, but 
plateauing after about 9 months (37).  
The mechanism of action when CD34+ cells are used for therapeutic 
neovascularization is still not completely understood. Early studies show evidence of 
differentiation of CD34+ cells into endothelial cells and cardiomyocytes after 
transplantation into nude mice following coronary artery ligation (61). However, other 
studies using non-human primate autologous CD34+ cells tagged with green fluorescent 
protein (GFP) found very few transplanted cells incorporated into the vasculature or in 
cardiomyocytes (173). Rather, these authors found that cultured CD34+ cells secrete 
angiogenic cytokines that promote angiogenesis in endogenous endothelial cells (173). 
Similarly, Wang et al., found that functional improvements in the hearts of severe 
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combined immunodeficiency (SCID) mice after experimental MI were due to 
improvements in angiogenesis and/or paracrine effects, but not a result of myogenesis 
(160). More recent studies have since supported this notion that CD34+ CACs function 
mainly through paracrine effects (145, 168). Indeed, Sahoo et al. (2011) found that the 
angiogenic effects of CD34+ CACs are mediated by secreted exosomes (125).  They 
found that conditioned media generated from CD34+ CACs promoted endothelial cell 
viability, proliferation and tube formation (125) and that CD34+ exosome-only treatment 
replicated the results observed in these in vitro experiments. In vivo treatment using 
CD34+ derived exosomes successfully stimulated angiogenesis using matrigel plug and 
corneal assays (125). Interestingly, when CD34+ conditioned media was depleted of 
exosomes or when exosomes from CD34+ -depleted MNCs were used these angiogenic 
activities were no longer evident, emphasizing the effects of paracrine factors, namely 
exosomes, in CD34+ CAC angiogenic actions.  
The survival of CACs after transplantation is another topic that is still under 
investigation. Using bioluminescence imaging, Wang et al. (2010) found that 
transplanted CD34+ cells survived in the hearts of SCID mice after experimental MI for 
more than one year after cell therapy (160). Other studies have shown that engraftment of 
transplanted CD34+ cells in human patients with MI is only ~5% 1 hour following 
injection and that these cells are retained preferentially in the peri- infarct zone of the 
heart (115). A larger, more recent study of 110 patients with dilated cardiomyopathy 
examined the effects of CD34+ transplantation after 5 years. Two hours after CAC 
treatment, engraftment was estimated to be ~7% and this decreased to 5% at 18 hours 
following injection as indicated through 99mTv-hexamethylpropylene-amine oxyme 
25	   	  
labeling. These investigators found that long-term survival, ventricular function, and 
exercise tolerance were greater in the group that received the cell therapy compared to 
controls at five years after cell transplantation (158). Improvements in left ventricular 
ejection fraction were greater in patients with better myocardial homing of injected CACs 
after 3 and 12 months. Thus, it appears that homing of CACs to the area of damage 
affects some outcome measures but that the long-term effects of CD34+ therapy may 
persist even if the cells have not engrafted into the endothelium. 
CD31+ CACs  
CD31, also known as Platelet endothelial cell adhesion molecule-1 (PECAM-1), 
is a cell surface marker most commonly found on mature endothelial cells, but it has also 
been identified on hematopietic cells (64, 79, 85), monocytes, granulocytes, platelets 
(167) and T cells (53). On endothelial cells, CD31 is involved in the maintenance of a 
vascular permeability barrier, regulation of transendothelial migration of monocytes and 
neutrophils, and in angiogenesis (78). Although not as commonly studied as CD34+ 
CACs for therapeutic neovascularization, CD31+ CACs have been found to exhibit a 
similar angiogenic potential as CD34+ CACs in terms of improving mouse hind-limb 
ischemia, emphasizing the importance of studying non-progenitor cell lines which may 
also be involved in angiogenesis (78).  Selected human CD31+ cells have been found to 
express higher levels of angiogenic genes compared to the CD31 depleted fraction (75, 
79). When injected into a mouse ischemic hindlimb, CD31+ CACs displayed high 
adhesion and vasculogenic capacity and augment blood perfusion preventing limb loss 
(75, 79).  
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Bone marrow-derived CD31+ cells have been identified as a highly angiogenic 
subgroup of mononuclear cells (75, 79). CD31+ cells exhibit an endothelial phenotype in 
vitro (79). Indeed, there has been at least one report of CD31+ CACs spontaneously 
forming tube-like formations in vitro that were positive for lectin and took up acetylated 
LDL, a characteristic similar to endothelial cells (79). Additionally, other studies have 
found that incorporation of CD31+ cells into the existing vasculature was significant, 
although transplanted cells accounted for only ~3% of the functional endothelial cells 
present in a mouse hindlimb ischemia model, despite an observed reversal in ischemia 
and 1.3 fold increase in capillary density (75). These results suggest that other 
mechanisms, such as paracrine function, are playing a more dominant role in the 
reparative activities of CD31+ cells. Indeed, Kim et al. has identified an upregulation of a 
number of angiogenic, anti-apoptotic and chemotactic factors in the ischemic limbs 7 
days after transplantation of CD31+ cells, providing support for paracrine activity as a 
major method of action in CD31+ CACs (75, 79).  
The cell surface markers present along with CD31+ on CACs may play a large 
role in determining their physiological function. Many studies have investigated 
angiogenic T-cells, which contain the marker CD31+ due to their roles in inflammation. 
Hur et al. (2007) found that CD31+/CD3+ T cells, but not CD31-/CD3+ cells constitute 
the central cluster of the CFU colonies and play an important role in vessel formation 
mainly through paracrine actions (52). In the clinical setting, these authors also found that 
the number of CD31+/CD3+ cells found in peripheral blood was inversely related to age 
and number of CV risk factors (52). Indeed, as with other CAC subtypes, CD31+/CD3+ 
cells are considered novel risk factors for CVD. Although the direct relationship between 
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CD31+/CD3+ CACs and clinical presentation of CVD has not been well explored, to 
date, there is evidence of increased number of CD31+/CD3+ CACs in patients with acute 
coronary syndrome compared to healthy controls (68). This difference was no longer 
evident 6 months after percutaneous coronary intervention suggesting that acute coronary 
events promote mobilization of CD31+/CD3+ CACs (68). Another study investigating 
healthy men between the ages of 21-70 years found that CVD risk and in vivo endothelial 
function was not associated with CD31+ T cell number. However, CD31+ T cell 
migratory capacity was positively correlated with forearm blood flow response to 
acetylcholine (Ach) and inversely related to Framingham Risk Score (164). Another 
study assessed the effects of age on CD31+ T cell number and function. Aging is 
associated with increased risk of CVD and progression of atherosclerosis due, in part, to a 
diminished endogenous vascular endothelial repair capacity. Kushner et al. (2010) found 
that older age (56-75 yrs) is associated with lower CD31+ cell number, reduced 
migratory capacity, shorter telomere length and reduced telomerase activity, and an 
increase in susceptibility to apoptosis compared to younger men (20-35 yrs) (86). 
Interestingly, these authors observed no differences in CD31+ number in middle-aged 
(36-55 yrs) versus younger men, suggesting that in healthy men, CD31+ number is 
preserved through middle age with the decline in cell number occurs after ~55 years of 
age (86).  These studies are important as they demonstrate the critical role of CD31+ 
CACs as a novel CV biomarker in both healthy populations and individuals with CVD 
and emphasize the role of not just CD31+ cell number but also the function of these cells 
in contributing to the repair and maintenance of the endothelium. 
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Importantly, expression of CD31 on leukocytes controls T cell activation and 
lymphocyte hyperactivity, which plays an important role in the regulation and 
stabilization of atherosclerotic plaques (34). Loss of CD31 regulatory signaling in T cells 
has been shown to promote atherlosclerosis (15). Flego et al (2014) found that CD31 
expression on T cells from patients with acute coronary syndrome was reduced compared 
to patients with stable angina, leading to reduced inhibitory activity in lymphocytes and T 
cell dysregulation (34). These findings suggest that CD31 expression is critical for the 
regulation of the immune response associated with atherosclerosis. Hur et al (2007) 
demonstrated that CD31+ T cells are able to form better tubules, have greater 
transendothelial migration, and have a greater ability to promote endothelial cell 
proliferation and function in vitro compared with other T cells subsets emphasizing the 
critical role of CD31+ CACs in angiogenesis (52). Indeed, others have found that 
CD31+/CD3+ CACs have better migratory capacity in response to SDF-1α and enhanced 
secretion of the angiogenic cytokines G-CSF, IL-8 and MMP-9, compared to CD31-
/CD3+ CACs, which they conclude may be contributing to the enhanced vasculogenic 
properties as compared to CACs lacking CD31 (84).  The enhanced migratory capacity of 
cells positive for CD31 may be attributed to greater surface expression of CXCR4 (98% 
compared to 38% in CD31- CACs), which is the receptor for SDF-1α (53).  
 Monocytes (CD34-/CD14+) cultured under angiogenic conditions have been 
found to take on an endothelial phenotype and form cord- and tube-like structures in in 
vitro (132). Importantly, CD31 is constitutively expressed on the surface of circulating 
monocytes. Others have found that many circulating progenitor cells express monocyte 
surface markers and function predominantly through secretion of angiogenic factors 
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(124). In fact, it has been shown that the majority of cells localized around newly-formed 
blood vessels are positive for the macrophage marker F4/80. Interestingly, F4/80 + and 
CD31+ cells do not exhibit markers for classic EPCs, suggesting that that bone marrow-
derived angiogenic monocytes are actually playing a large role in supporting 
angiogenesis that was originally thought to be reserved for progenitor cells (51). 
Circulating blood macrophages expressing CD31 have also been found to contribute to 
the formation of new blood vessels. In a parabiosis mouse model, CD31+ macrophages 
tagged with GFP were present in the walls of new vessels in wounds, gel foam blocks 
and tumors of the wild-type mouse, demonstrating that monocytes expressing both CD31 
and macrophage surface markers could be recruited to areas of tissue injury to assist in 
repair and new blood vessel formation (77). 
In young healthy men, CD31+/CD34- cells positive for the monocyte marker 
CD14 exhibit significantly higher levels of intracellular ROS after consumption of a high 
fat meal, which is completely prevented with prior endurance exercise (64). This 
indicates that intracellular redox balance in CD31+ monocytes is affected by 
environmental stimuli, and emphasizes the importance of studying the health of CAC 
when considering these cells for autologous therapies. Indeed, reports of contribution of 
CD31+ cells in the development of atherosclerosis in areas of disturbed flow in ApoE-
deficient mice indicate that these cells can also have inflammatory properties (42). A 
recent study found that CD31+ cells from human patients with coronary artery disease 
(CAD) exhibited impaired angiogenic potential and expressed lower levels of pro-
angiogenic genes compared to healthy counterparts. There were significant correlations 
between the number of CD31+ cells and severity of coronary artery disease (76). 
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Interestingly, this study performed flow cytometry analyses to characterize the cells and 
found that the selected CD31+ cells of CVD patients were composed mainly of 
monocytes/macrophages (CD14 and CD11b), whereas the selected CD31+ cells of 
healthy individuals were composed of mostly T-cells (CD3) (76). Both cell types have 
been found to secrete factors that promote angiogenesis, however, monocytes and 
macrophages have also been associated with inflammation. This study also found an 
upregulation of pro-inflammatory genes and down regulation of angiogenic genes in the 
CD31+ CAC of CAD patients compared to healthy controls, suggesting that the cells 
from this patient population may be involved in the inflammatory process of 
atherosclerotic plaque development (76). These authors conclude that CD31+ cells from 
CAD patients may serve as a source of inflammatory factors contributing to the etiology 
of CAD. For this reason, caution must be used when using autologous CD31+ cells for 
therapeutic purposes to treat patients with established CVD.  
 To our knowledge, there have been no clinical trials to date that utilized purified 
CD31+ cells for autologous therapy in humans. However, there are a number of 
advantages to using CD31+ cells as opposed to EPCs or other circulating stem cells for 
therapeutic purposes. Among these advantages include a greater abundance of CD31+ 
cells present in circulation, and the ability to use these cells after isolation from PBMCs 
without the use of in vitro culture (75). More than 90% of hematopoietic stem cells, 
multipotent progenitor cells, lymphoid progenitors and monocyte progenitor cells express 
CD31 (78). In human bone marrow derived cells, nearly 100% of CD34+/CD133+ cells 
were positive for CD31 and 89% of CD34+/CD133- cells were positive for CD31 (78). In 
addition, CD31+ have greater adhesion capacity to extracellular matrices such as laminin, 
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collagen and fibronectin compared to CD31- cells giving them a greater chance of 
survival and engraftment when used for therapeutic purposes (78).  
Discordant Findings in CAC Therapies 
As the use of CACs for therapy for ischemic CVD is a relatively new concept, it 
is important that the major differences in CAC treatments are explored to best optimize 
the therapeutic use of CACs for both primary and secondary CVD therapy. To this day, 
the agreement on the best type of CAC for autologous therapy has been disputed (Bone 
marrow, PBMC, preselected, culture, etc.).  Many trials use bone marrow aspirations as 
an attempt to isolate more immature cells with greater plasticity.  However, the results of 
these trials are not very successful (37, 120, 121), suggesting that more differentiated or 
mature cells may have a greater functional capacity.  Along the same lines, total MNCs 
are still being used for some trials.  The rationale behind the use of total MNCs as 
opposed to a single selected cell type, involves the physiological relevance as in vivo 
conditions involve a complex cell-cell communication with other circulating immune and 
hematopoietic cells.  While this may be true, it does appear based on the studies listed 
above, that the CD34+ and CD31+ populations are of critical importance and have 
overall better outcomes compared to MNCs (72, 120, 125).   
Similarly, the protocol for isolating or identifying these cells as well as the model 
used to test their function can also affect the clinical relevance. For example, it has been 
suggested that OECs are products of angiogenic culture conditions and, therefore, may 
not exist in the systemic circulation (29). How these cells would then behave if re-
introduced to the body is not yet established. Additionally, there are various combinations 
of cell markers that are currently being used in clinical settings. The greater number of 
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cell markers required means these cells become more rare, limiting what they can be used 
for.  The type of “injury” induced in animal models (hind limb ischemia, experimental 
MI, denuded mouse, etc) could affect the outcomes of the study in the case that the 
specific stimuli preferentially recruit certain subsets of CACs.  Along the same line, since 
many of the CD34+ subpopulations of CACs are very rare in vivo, some investigators use 
mobilizing agents to recruit more cells.  The effects of these mobilizing agents on the 
CACs function have not yet been well explored. 
The dose or potency of the CAC treatment has also been explored with lower cell 
doses of more purified cell populations showing the most success (95). Additionally, the 
mode of delivery (intracoronary injections, systemic, pericutaneous, etc.) may also play a 
role in the ability of the CAC to reach the site of injury and in long-term retention. 
Finally, the timing of treatment based on disease severity or time following an acute 
event is also critical and it is still not optimized. 
The best outcome measure to test whether the CAC therapy is successful is also 
not yet established.  To date, the majority of clinical trials using CACs to treat MIs use 
left ventricular ejection fraction as a major outcome measure.  However, a more recent 
study (115) suggests that for detection of improvements in CAC therapy after a MI, a 
better indicator is to measure infarct size. Thus, it is possible that as we learn more about 
CACs, we will also find better means of establishing CAC function in vivo and functional 
outcomes of the heart or other ischemic tisses as a result of CAC therapy. 
Finally and potentially one of the largest contributors to the discordant findings in 
the therapeutic use of CACs to treat CVD has to do with the autologous nature of the 
cells. In many cases, CACs are being harvested from patient populations.  As mentioned 
33	   	  
earlier, there is a negative relationship between the function of CACs and the severity of 
CVD.  Thus, CACs from patients who recently suffered an acute event likely have lower 
functioning CACs compared to healthy adults. Since these lower functioning cells are 
being re-introduced this could contribute to the inconsistent findings with these 
treatments.   
Role of Oxidative Stress, Nitric Oxide and Inflammation on CAC Function 
As mentioned above, one of the critical issues with the use of autologous CAC 
therapy has to do with the fact that the CACs isolated from patient populations, those 
who might require stem cell therapy are low-functioning compared to healthy individuals. 
The cells from most CVD patients are exposed to chronically high levels of inflammation 
and oxidative stress and are often from individuals older in age. Indeed, lower 
functioning CACs have been identified in cases of atherosclerosis/CAD, obesity, type II 
diabetes, etc. with the function of CACs declining with the addition of more risk factors 
(35) (Figure 2.3).  For example, in the metabolic syndrome, the combination of obesity, 
dyslipidemia, hypertension and hyperglycemia all contribute to the decreases in CAC 
function and improvements in even just one factor has been shown to elicit some 
improvements (14, 35). This has also been evident in cases such as smoking cessation 
and exercise training, two interventions that are associated with decreasing whole body 
















Figure 2.3 A number of environmental and pathophysiological factors generate 
oxidative stress, which affects CAC function and consequently impair endothelial 
repair. Oxidative stress results in greater levels of NAHPH oxidase and eNOS 
uncoupling leading to CAC dysfunction. Dysfunctional CACs cannot adequately 
contribute to vessel repair or neoangiogenesis. Figure adapted from Fleissner and Thum 
(2011)(35). 
 
The common factor in most of these chronic conditions and likely the greatest 
contributor to CAC dysfunction is decreased NO bioavailability. A key study that 
addressed the critical importance of eNOS and NO in CAC number and function was 
performed by Aicher et al. (2003) who found that revascularization after hindlimb 
ischemia was impaired in eNOS knockout mice.  However, when CACs from wild type 
animals were introduced into the animal this affect was attenuated (1). This study 
emphasized the critical importance of eNOS-derived NO at the site of neovascualrization 
in order for CACs to function properly. Indeed, eNOS- derived NO is a major regulator 
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well as the intracellular function of CACs. In a healthy young adult, extracellular 
physiological NO activates MMP9 within the bone marrow, which, after subsequent c-kit 
ligand splicing, mobilized CACs from the bone marrow into the circulation (35). Once in 
the circulation, CACs travel to an area of damage based on chemokine attraction.  The 
ability of the CAC to perform this task involves physiological intracellular NO. eNOS 
activation within the CAC results in an increase in VEGF expression, which contributes 
to the proliferative and angiogenic properties of the cell. eNOS-derived NO also 
contributes to cytoskeletal changes and increases in vascular-stimulated phosphoprotein 
(VASP), which improve the migratory responses of CACs to the angiogenic stimuli 
coming from the site of injury. eNOS-mediated NO can also affect transcription factors 
within the cell nucleus and, thus, transcription of angiogenic genes, further enhancing the 
vasculo-protective and angiogenic capacity of CACs (35). 
The endogenous eNOS inhibitor, asymmetric dimethylarginine (ADMA) is 
elevated in disease conditions such as coronary artery disease and atherosclerosis. 
Elevated extracellular levels of this factor can be taken up by CACs and lead to decreased 
NO bioavailability (35). One mechanism through which this has been found to occur 
involved the up regulation of microRNA-21 in CACs in response to high circulating 
ADMA concentrations. miR-21 targets superoxide dismutase 2 resulting in a repression 
of antioxidant capacity and decreased protection against oxidative stress.  miR-21 also 
targets sprouty-2 which results in an increase in intracellular oxidative stress through an 
MAPK/ERK dependent mechanism. This combination between increased intracellular 
oxidative stress and decreased protection from oxidative stress contributes to the ROS-
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dependent decrease in intracellular NO bioavailability (35). Together this creates a 














Figure 2.4 A number of factors such as age, diabetes and ADMA can affect 
intracellular signaling of CAC and lead to CAC dysfunction, which consequently 
impairs vascular repair and leads to progressive vascular injury. Figure adapted from 
Fleissner and Thum (2011) (35). 
 
Aging is associated with an increase in visceral adiposity, increased oxidative 
stress and inflammation, and decreased production of growth factors (IGF-1, GH, 
VEGF).  Growth factors affect the health of CACs by activating eNOS and up regulating 
NO bioavailability (35). VEGF is also involved in the mobilization of CACs from the 
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production of these growth factors is compromised, there is a decrease in intracellular 
eNOS activation resulting in decreased NO bioavailability and a dysfunctional CAC, 
impaired repair capacity and as a result, further progression of the disease (Figure 2.4).   
Inflammation associated with obesity also can have detrimental effects on CAC 
function. In an atherogenic environment CACs can become activated and take on more of 
a monocytic fate where they infiltrate into the subendothelial space and turn into foam 
cells, further secreting angiogenic and inflammatory factors (21, 56, 100, 105). Initially 
this is an attempt to stabilize plaque development, but over time these foam cells can 
contribute to an unstable plaque and plaque rupture.  The ability of CACs to take on a 
foam cell phenotype is affected by the extracellular environment and an increase in pro-
inflammatory factors and lipids often found in obese populations (21, 100, 169). 
Additionally, oxidized LDL has been found to decrease eNOS activity and NO 
bioavailability, while lipid apheresis is reported to rescue eNOS activity and enhance 
CAC function (35).  
Hyperglycemia and type II diabetes are other conditions that lend to an 
extracellular environment with elevated oxidative stress and inflammation (Figure 2.4). 
High plasma glucose affects CACs by increasing levels of NADPH oxidase leading to 
eNOS uncoupling, thereby decreasing NO bioavailability and further increasing 
intracellular ROS (139). In vitro assays have found that CACs cultured in a high glucose 
environment exhibited decreased adhesion, lower proliferative capacity and impaired in 
vitro tube formation (67).   
The notion that a variety of diseases can modify CAC function has become 
increasingly recognized. As such, and due to the autologous nature of CAC therapies, 
38	   	  
researchers have been looking for ways to enhance the function of CACs from patient 
populations before using them for transplants. Mackie et al., found that genetically 
modifying CD34+ CACs to overexpress sonic hedgehog (shh) better preserved cardiac 
function when these cells were injected into mice after experimental acute MI (102). 
Other labs have used adenoviral infection to upregulate antioxidant or angiogenic 
pathways. Ex vivo transduction of CACs with akt/HO-1, key factors involved in cell 
survival and angiogenesis, resulted in decreased CAC senescence and increased 
protection from pro-oxidative factors (13). Additionally, adenoviral infection with VEGF 
has been found to improve the ability of CACs to respond to hindlimb ischemia via 
increased neovascularization and increased paracrine release of VEGF (58).  These 
studies suggest that the future of CAC therapy might lie in the ability to enhance the 
function of cells from diseased individuals, perhaps using a combination of factors that 
are enhanced or downregulated in optimally functioning populations. 
Exercise and CAC Function 
Recently, there has been an emphasis on improving the function of CACs to be 
used for autologous cell therapies to treat lower functioning CACs from individuals with 
known pathologies and/or enhance their reparative properties. However, it is important to 
consider potentially negative outcomes associated with genetic or pharmacological 
treatments if the proper balance is not found. There have been a number of studies that 
explore the effects of both acute and chronic exercise on different populations of CACs in 
healthy and diseased populations (82, 156). The vast majority of these findings provide 
support for the beneficial effects of exercise to enhance CAC function. Our lab has 
identified young endurance exercise trained individuals as an ideal population to guide 
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mechanistic intervention therapies to enhance CAC function. Indeed, we have found that 
aerobic exercise is an ideal treatment for both enhancing CAC function as a preventive 
measure and as a model to allow assessment of the molecular mechanisms associated 
with optimal CAC function. Thus, identification of the mechanisms underlying the 
improved extracellular and intracellular environment in exercise-trained individuals 
provide potential targets to improve the function of CACs and could serve as a promising 
therapy for CVD.  
Acute Exercise 
 Acute aerobic exercise is a known stimulus for increasing circulating 
concentrations of CACs. Mobius-Winkler et al. (2009) found that cycling continuously 
for 4 hours at 70% of an individual’s ventilatory threshold caused a time-dependent 
release of CD34+ and CD34+/VEGR2+ CACs. They noted that number of both CAC 
populations was highest 3.5-4 hrs into the cycling bout (109) and slowly declined over a 
period of a few hours upon completion of exercise. It was also discovered that the rise in 
CACs was preceded by an early rise in VEGF and later, IL-6 which are believed to serve 
as signals to mobilize CACs from bone marrow and into the circulation (109). Another 
study found that an acute exercise bout substantially shorter than that in the Mobius-
Winkler paper (~20 min vs 4 hrs) significantly increased circulating CD34+ CAC number 
in both young and older men (138).  
Importantly, differences in CAC number and function have also been observed in 
younger adults as a function of chronic aerobic exercise habits. Jenkins et al. (2009) 
observed a differential response to an acute submaximal exercise bout in younger inactive 
vs. active adults (66). No differences in CFU numbers were observed at baseline, 
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however, mRNA levels of the pro-oxidative enzyme gp91phox were higher and eNOS 
mRNA was lower in the CACs of inactive relative to active individuals. After the acute 
exercise CFU number increased in the active group only and corresponded with reduced 
mRNA expression of pro-oxidative enzymes. Conversely, acute exercise increased 
inducible NO production in inactive individuals (66). Another study by Jenkins et al 
(2011) found that increases in intracellular ROS in CD31+ CACs of younger adults 
caused by consumption of a high fat meal were completely prevented when an acute bout 
of exercise was performed on the prior day (64).  
Acute exercise can also have a beneficial effect for diseased populations. Chronic 
heart failure patients with impaired endothelial and CAC function exhibited 
improvements in CAC migratory function with just one acute bout of exercise (146). In 
the same study, CD34+ and CD34+/VEGFR2+ CAC number, however, remained 
unchanged. Beneficial effects have also been observed in PAD patients after one acute 
bout of exhaustive exercise. Although numbers of CD34+/VEGFR2+ CACs were similar 
at baseline between healthy controls and PAD patients, CD34+/CD133+ CACs were 
lower in PAD subjects and acute exercise significantly increased CD34+/CD133+ CAC 
number (135).  As one acute bout of exercise has the ability to improve CAC number and 
function, we can speculate that regular participation in aerobic exercise would provide a 
overall protective effect on CACs. 
Exercise Training 
It is well known that regular aerobic exercise training is associated with 
improvements in circulating lipid profiles, reductions in oxidative stress, decreased 
inflammatory response, and up regulation of endogenous antioxidant capacity, all of 
41	   	  
which contribute to an increase in NO bioavailability. Regular aerobic exercise is also 
associated with increases in CAC number in both healthy and diseased populations, 
regardless of age, and this is typically correlated with improvements in endothelial 
function (166, 170). In one study, older and younger men participating in 30 min of 
aerobic exercise 3 times/week for 3 months showed significant elevations in 
CD34+/KDR+ CACs and this was associated with decreases in brachial-ankle pulse wave 
velocity (baPWV) (170). In fact, after the 3 month training period, CAC number, 
migratory capacity and proliferative activity as well as baPVW in older adults was 
similar to those of younger adults, suggesting that regular aerobic exercise can attenuate 
some of the age-related decline in arterial elasticity via increased CAC number (170).  
The effects of exercise on CAC number and function are at least partially 
mediated by shear stress. Indirectly, shear stress acting on the endothelial wall results in 
increases in VEGF and NO, which are known to mobilize CACs from the bone marrow 
(35). Once in circulation, and/or localized to an area off damage, shear stress acts directly 
on the CACs through various signaling pathways (117, 168) to enhance CAC function. In 
fact, one study exposed lower functioning CACs from older adults to shear stress and 
found improvements in cell migration, adhesion, and re-endothelialization capacity of 
these CACs (168). There is also evidence that exposure of CACs to shear stress 
upregulates integrins β1 and β3, which results in increased adhesion and differentiation 
toward a more endothelial phenotype (20).  
Another study assessed at the effects of 3 months of regular aerobic exercise on 
CFU CACs in middle-aged and older men and found that although CAC migration was 
initially reduced in older compared with young and middle aged men, the exercise 
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intervention increased both CFU number and migratory capacity in both middle-aged and 
older adults (50). Interestingly, another study examining the effect of ageing and exercise 
on CACs found that irrespective of age, aerobic exercise training (8 weeks, 3x/wk for 30 
min betwwen 65-85% heart rate reserve) did not affect baseline or acute exercise-induced 
numbers of CD34+ CACs (138). Similarly, Witkowski et al. (2010) found no difference 
in baseline numbers of CD34+ or CD34+/VEGR2+ CACs of CFU colonies in older 
inactive individuals compared to masters athletes, but did see a substantial reduction in 
CD34+ cell number after just 10 days of exercise cessation in the older adults. These 
findings were closely related to a physical activity dependent changed in reactive 
hyperaemic forearm blood flow measurements (166). As advanced age is an independent 
risk factor for developing CVD, it is promising to consider the preventive effects of 
aerobic exercise in older populations to protect them from potential future cardiac events.  
Importantly, differences in CAC number and function have also been observed in 
younger adults as a function of chronic aerobic exercise habits (10). Intracellular ROS 
and NO levels were found to be significantly higher in the CD34+ CACs from inactive 
men compared to endurance-trained men along with greater iNOS and lower eNOS 
mRNA expression, suggesting a link between the physical inactivity and nitro-oxidative 
stress (63). Importantly, these differences were eliminated after one acute bout of 
exercise (63). Another study assessed the effects of reduced physical activity on CD34+ 
CACs and CFU CACs in younger adults. They found that 10 days of reduced physical 
activity resulted in lower CFU CAC numbers and reduced intracellular NO levels, but 
had no effect on CD34+ CAC number or intracellular NO (40), suggesting that the effects 
of exercise on CAC number and function might be cell-type specific. A recent study in 
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our lab found significant differences in paracrine activity of CD34+ and CD34-/CD31+ 
CACs as a function of habitual activity with lower HUVEC tube formation observed 
when CM from inactive individuals was used compared to CM from active and high 
endurance-trained individuals (87). Additionally, it appears that the differences in tube 
formation were at least partially due to a greater secretion of S100A8 and S100A9 
proteins from CD34-/CD31+ CACs of inactive individuals. Interestingly, in this study, 
there were no observed differences in intracellular ROS or NO as a function of chronic 
exercise habits (87). 
Although as a whole, exercise training does appear to be beneficial for CAC 
function, it is important to note that there have been some studies that did not observe 
differences in CAC number as a result of training. Rakobowchuk et al. (2012) found that 
CD34+ CAC number was higher after 6 weeks of heavy interval exercise training, 
although high variability among subjects made this increase actually not statistically 
significant (122). The subjects in this study were younger healthy individuals, suggesting 
that in populations already exhibiting high CV function, the effects of exercise on CAC 
mobilization can be highly variable.  
It is important to study CAC number and function in younger healthy individuals 
of varying levels of physical fitness to determine whether differences can be detected 
before classic CV risk factors are observed. However, as individuals with various forms 
of CVD are the target group theoretically receiving CAC therapy, it is vital that we 
identify what properties of CACs are limiting the potential of these cells to be 
successfully utilized for autologous treatments and whether mechanisms associated with 
exercise can help improve this. Indeed, exercise training can also have beneficial effects 
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of CAC number and function in a number of CVD settings (33, 91, 131, 136, 146, 148). 
For instance, CACs from individuals with metabolic syndrome have decreased functional 
capacity when tested in a nude mouse denuded artery model. After 8 weeks of exercise 
training, CACs from these same individuals significantly improved re-endothelialization 
and decreased size of denuded area (136). Exercise training has also been beneficial for 
heart failure patients who exhibit CAC and endothelial dysfunction compared to healthy 
controls. Van Craenenbroeck et al. (2010) enrolled chronic heart failure patients in 6 
months of exercise training and found that CD34+/VEGFR2+ CAC number and 
migratory capacity were substantially improved along with improvements in peripheral 
endothelial function (148). Six months of supervised walking can also improve CAC 
number and endothelial function, accompanied by decreases in the NO-inhibitors ADMA 
in patients with peripheral artery disease (PAD)(131). Interestingly, these benefits were 
not observed in a group receiving just medical treatment for PAD. It is important to note 
that structured exercise programs are not required in order for beneficial changes in CAC 
number and function to take place. Activities of daily living have been shown to be 
positively correlated with CD34+/VEGFR2+ CAC number, with total activity being 
positively associated with colony forming capacity of CD34+ CACs in coronary artery 
disease patients after suffering from a MI (83).    
The promising effects of exercise training have begun to enter into the clinical 
realm as Domanchuk et al. (2013) has initiated a PROgenitor cell release Plus Exercise 
(PROPEL) trial to improve functional performance in patients with PAD. This study will 
examine whether granulocyte-marophage colony stimulating factor (GM-CSF) treatment 
combined with supervised treadmill walking or each therapy alone will improve 6-minute 
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walk distance, brachial artery flow mediated dilation (FMD) and CD34+ cell number 
after 12 weeks (24). As there are a number of benefits to exercise in addition to improved 
CAC function, it is likely that more clinical trials such as this one will be performed in 
the future to assess them as viable options for treating CVD. 
Paracrine Functions 
As described briefly above, there are some cases of both CD34+ and CD31+ 
CACs engrafting into the endothelium (4). However, studies using GFP tagged CACs for 
bone marrow transplantation (175) or in a parabiosis model have found that very few, if 
any, transplanted CACs actually incorporate into the existing vasculature. One study 
transplanted bone marrow expressing GFP in mice and 6 weeks after transplantation the 
mice underwent unilateral femoral artery occlusion. Investigators found that despite 
improvements in hindlimb collateral artery growth, there was no GFP signal within 
endothelial or smooth muscle cells (173). They did, however, find significantly greater 
accumulations of GFP-tagged cells alongside collateral arteries in the ischemic limb 
compared to the non-occluded side. These findings support the notion that incorporation 
of bone marrow-derived CACs into the vasculature is not required for angiogenic effects, 
rather they are likely functioning as supporting cells to aid in angiogenesis (175).  
It is now generally accepted that CACs function predominantly through paracrine 
mechanisms. One of the first major reports of CAC paracrine activity assessed secreted 
factors from CACs cultured in normal and hypoxic conditions. They found a number of 
angiogenic cytokines in the media including VEGF, PIGF, bFGF and MCP-1 after 72 
hours and the CM from these CACs promoted endothelial cell migration and proliferation 
in vitro (80, 81). Additionally, in vivo experiments using a mouse hindlimb ischemia 
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model found enhanced recovery, greater collateral artery growth, improved limb function 
and lower muscle atrophy when CM was used compared to control media (80). This and 
other studies performed by this lab also demonstrated that CACs assist in collateral 
remodeling after hindlimb ischemia in mice through paracrine mechanisms (80, 81). 
Other studies have found that CM derived from CACs helped reduce myocardial 
inflammation associated with autoimmune myocarditis (49) and myocardial infarction 
(54). In vitro studies have found that co-culture of CD34+ CACs with HUVECs, so that 
they shared the same environment but were kept from directly interacting, resulted in 
increased sprout lengths of HUVEC spheroids (129) and identification of a number of 
secreted factors in the shared CM. 
 Several angiogenic factors have been identified in the secretome of various types 
of CACs. To date, the vast majority of research has been focused on secreted proteins 
(80, 81, 145, 168), namely angiogenic factors or growth factors with known roles in 
angiogenesis. However, more recently there has been a body of literature directed at the 
identification of microRNAs secreted by CACs. Recently, microRNA-126 and 
microRNA-130a have been identified in the cell secretome of CD34+ CACs, primarily 
packaged within exosomes and that these are largely mediating the observed 
proangiogenic effects of these cells (125). Mocharla et al. (2013) found that CD34+ cells 
and CM derived from CD34+ CACs exerted superior proangiogenic actions as assessed 
by tube formation compared to CM from CD34- CACs. They also discovered that 
microRNA-126 was secreted from CD34+ CACs in exosomes and that inhibiting the 
release of microRNA-126 by transfection of CACs with anti-miR-126 impaired these 
proangiogenic actions. Angiogenic actions were also impaired due to reduced secretion of 
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microRNA-126 from CD34+ CACs from individuals with type II diabetes, but treatment 
with a microRNA-126 mimetic rescued these actions (110). Although it is also believed 
that CD31+ CACs function predominantly through paracrine functions as well, secretion 
of exosomes and accompanying microRNAs from this subset of CACs has not yet been 
well explored. These studies emphasize the importance of exploring secreted factors in 
addition to just cytokines that may be mediating the proangiogenic effects of CACs. 
 The mechanisms behind the paracrine activities of CACs have not yet been fully 
explained. It has been found that overexpression of integrin β5 enhances the reparative 
paracrine functions of CACs through phosphorylation of integrin ανβ5 and subsequent 
activation of Src Kinase and signal transducer and activator of transcription (STAT)3. 
CM from these CACs successfully enhanced human endothelial cell sprouting using a 
spheroid assay compared to CM from vector-treated CACs (90). They also found 
elevated levels of angiogenic cytokines CCL2 and CXCL8 in the CM of the integrin β5 
enhanced CACs.  
As our lab has previously found, both acute and chronic physical activity and diet 
can affect the intracellular redox balance within both CD34+ and CD31+ CACs (63, 64, 
66). However, we have since found significant differences in angiogenic tube formation 
in both CD34+ and CD34-/CD31+ CACs as a function of chronic physical activity in 
younger men and women despite no observed differences in intracellular ROS and NO. 
As such, it appears that at least in the case of younger individuals, paracrine function is 
not mediated by intracellular redox balance (88). However, other studies have found that 
antioxidant supplementation affects cytokine production by monocytes after an acute 
bout of exercise, suggesting that if redox balance is involved, the mechanisms may be 
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cell-specific or require stimulation of some cells (i.e.- exercise) to have a significant 
effect (141). Other mechanisms affecting the paracrine function of CACs, to our 
knowledge, have not yet been explored. 
Although some focus has been placed on identifying mechanisms of paracrine 
release as a consequence of intracellular health, it is also likely that paracrine factors are 
differentially released or expressed depending on the microenvironment that the CACs 
encounter (38). The released factors can then affect the surrounding tissues and/or the 
CACs themselves as a result. Indeed, environmental stimuli such as ischemia can alter 
Akt-mediated release of soluble factors from CACs, which then act in an autocrine 
manner to influence further CAC actions (i.e. proliferation) or a paracrine manner, acting 
on surrounding endothelial cells, smooth muscle cells or cardiomyocytes to induce repair 
or regeneration (38). 
As mentioned above, the health of the cell donor is one of many factors that may 
be contributing to some of the discordant findings among CAC therapies. To date, the 
majority of studies investigating paracrine actions of CACs have focused on growth 
factors that are believed to enhance angiogenesis. As it is generally accepted that CACs 
from older or diseased individuals function poorly, we can assume that this means there 
is a good chance that these CACs are potentially secreting pro-inflammatory or anti-
angiogenic factors that may disrupt “normal” angiogenic behaviors.  As mentioned 
previously, we have found that there are significant differences in the secretion of 
inflammatory proteins S100A8 and S100A9 from CD34-/CD31+ CAC as a function of 
habitual physical activity levels in younger healthy adults. CM from CD34-/CD31+ 
CACs of inactive individuals contained twice as much S100A8 and S100A9 as CM from 
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their endurance-trained counterparts. Additionally, tube formation was reduced when 
concentrations of S100A8 and S100A9 similar to those found in the CM of inactive 
individuals’ CACs were used in the assay (88). These findings suggest that these 
proteins, and possibly others, are at least partially explaining the differences in CAC 
function found as a result of lifestyle. 
S100A8/S100A9  
Structure and Function 
S100A8 (aka MRP8 or calmodulin A) and S100A9 (aka MRP14 or calmodulin B) 
are small molecular weight proteins (11 KDa and 14KDa, respectively) that belong to the 
S100 family of calcium-modulated proteins. They are abundantly expressed in myeloid 
cells and their expression may be related to a certain stage of myeloid differentiation, as 
some studies indicate that expression is present in neutrophils and monocytes but is no 
longer evident in mature macrophages (74), while others have found that CD68+ 
macrophages in rheumatoid arthritis patients expressed antigens for S100A8/A9 (137). 
Meanwhile, others have found that expression patterns of both S100A8 and S100A9 in a 
number of cell types are dependent on the type and severity of the inflammatory 
condition (74). Expression of S100A8 and S100A9 has also been found in some epithelial 
and vascular cells (74, 153). However, surface expression of S100A9/A9 is not required 
for secretion of these proteins (74). Importantly, S100A8 and S100A9 are both expressed 
and secreted by CACs (31, 88, 145). 
S100A8 and S100A9 are released by a novel secretory pathway that is distinct 
from the classic endoplasmic reticulum/Golgi pathway (123, 153). Secretion is dependent 
on an intact microtubule network and involves the activation of protein kinase C (74, 
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123). However, there is also evidence of passive release of S100A8/A9 from necrotic 
cells after tissue damage (153).  
S100A8 and S100A9 can function independently as homodimers, bound together 
as a S100A8/S100A9 heterodimer (aka calprotectin), as well as in heterotetramer forms 
(74, 153). Self-assembly of these proteins into different structures is largely influenced by 
the Ca2+ and Zn2+- binding properties. Indeed, elevated Ca2+ levels present in 
mononuclear cells in inflammatory environments trigger the cytosolic monomers of 
S100A8 and S100A9 to translocate to the cell membrane where they form the more stable 
heterodimer complex (27). Furthermore, the structure of these proteins has been found to 
dictate their function, leading to a wide functional diversity of S100A8 and S100A9 (153) 
with the heterodimeric complex being the predominantly occurring, most stable and most 
physiologically relevant form (18, 48, 153). Eue et al., demonstrated that S100A8 and 
S100A9 can specifically bind to human endothelial cells with enhanced binding capacity 
of S100A9 over S100A8 and the heterodimer complex having the greatest capacity to 
bind to endothelial cells (27). At least one study has also found that S100A8 can regulate 
S100A9 activity through formation of the S100A8/A9 heterodimer (116). It should be 
noted that multiple forms of these proteins can exist in parallel and currently, there is no 
method for detecting the fractions of homodimers, heterodimers or functional effects of 
each of these if all are present simultaneously (153). 
These proteins can perform a wide variety of intracellular and extracellular 
functions and are involved in both normal physiological signaling and processes and a 
number of disease pathologies including inflammatory conditions, autoimmune diseases, 
cancer and atherosclerosis (74, 153). High levels of S100A8/A9 in the circulation have 
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been found in inflammatory disorders such as cyctic fibrosis, rheumatoid arthritis, and 
crohn’s disease (137). More recently, high systemic S100A8/A9 levels have also been 
linked to a number of different CVDs (5, 17, 18, 43, 130, 153) and also to several CV 
risk factors such as smoking, hyperlipidemia, hyperglycemia, and obesity (130) (Figure 
2.5) 
 
Figure 2.5. Overview of the interplay between S100A8 and S100A9, traditional CV 
risk factors, circulating phagocytes, and atherogenesis. Figure retrieved from Schiopu 
et al. (2013) (130). 
 
 
S100A8 and S100A9 function in a cytokine- or chemokine-like manner through 
binding to one of their many receptors, however the precise functions and molecular 
signaling mechanisms are not completely understood (74, 118). Receptors for S100A8 
and S100A9 include the receptor for advanced glycation end products (RAGE), Toll-like 
receptor 4 (TLR4), and CD36 (11, 26, 153, 155, 162). There are some reports that 
S100A8 preferentially binds to TLR4 while S100A9 preferentially binds to RAGE (153, 
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162), both of which are present on endothelial cells. Both homodimers and the 
heterodimer complex have the ability to interact with either receptor, which are often 
present on the same cell line, but it is believed that only one receptor is likely used at a 
given time (153). Downstream of these receptors, a signaling cascade is initiated which 
results in the phosphorylation of ERK1/2 and p38 leading to activation of the 
transcription factor nuclear factor-κB (25, 137, 153, 162) (Figure 2.6). Upon binding to 
their receptors, S100A8/A9 can perform a number of functions including stimulation of 
neutrophil adhesion via β2 integrins (74), and promotion of leukocyte trafficking and 
leukocyte-endothelial cell interaction (154)leading to activation of the microvascular 
endothelium, loss of endothelial barrier function and upregulation of thrombogenic 



















Figure 2.6. Proposed pathway through which S100A8/S100A9 act on endothelial 
cells. S100A8 and S100A9 bind to two major receptors present on endothelial cells, 
RAGE and TLR4, which triggers downstream signaling pathways that result in 
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Indeed, the role of S100A8/A9 in CVD has recently become clearer. Elevated 
circulating levels of S100A8/A9 are considered independent risk factors for a number of 
CVDs (71) with plasma levels predicting future CV events in middle-aged healthy 
individuals (17, 18, 43). One study found that serum levels of S100A8/A9 were 
significantly higher in patients with an acute MI compared to patients with unstable 
angina and that the levels of these proteins in the MI patients positively correlated with 
peak white blood cell and neutrophil counts, and peak levels of creatine kinase and C-
reactive protein (71). These proteins also play a functional role in the pathogenesis of 
inflammatory CV disorders with an activated endothelium being a major stimulator for 
surrounding monocytes to secrete S100A8/A9 and promote adhesion and transendothelial 
migration of inflammatory cells (27). For example, TLR4 activation by S100A9 
promotes an inflammatory response through activation of NF-κB, which induces 
expression and secretion of the pro-inflammatory cytokines IL-1β, IL-6, IL-8, IL-10, and 
TNF-α (137). Similarly, HUVECs treated with the S100A8/A9 heterodimer, but not with 
either homodimer, enhanced secretion of IL-6, ICAM-1, VCAM-1 and MCP1 via RAGE-
ERK1/2-p39- NF-κB mediated pathway (25). S100A8/A9 is specifically expressed in 
neutrophils and macrophages, which have infiltrated an infarcted myocardium (71) and 
are specifically secreted upon interaction between phagocytes and activated endothelium 
(36). Indeed, S100A8/A9 is a critical component in the response to vascular injury as 
indicated by significant reductions in leukocyte accumulation and neointimal formation 
after femoral artery injury in S100A9-deficient mice compared to wild-type mice (18). 
Similarly, prolonged time to arterial thrombic occlusion has been observed in S100A9 
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knockout mice, with infusion of platelets expressing S100A8/A9 from wild type mice 
substantially reducing time to carotid occlusion after vascular injury, indicating that 
platelet-derived S100A9 is involved in the regulation of thrombosis (163). 
The concentration of S100A8 and S100A9 in in vitro experiments appears to 
influence the inflammatory effects. For example, at low concentrations (up to 10ug/mL), 
S100A8/A9 has been found to promote angiogenic activity in vascular endothelial cells in 
both the homodimer or heterodimer form (92). As such, lower concentrations are 
believed to promote the growth of tumor cells and tumor cell migration (92, 153). 
Conversely, high concentrations have been found to have apoptotic effects on tumor 
cells, endothelial cells and other tissues (154). Indeed, Viemann et al. (2005) found that 
high concentrations of S100A8/A9 (200ug/mL) upregulated expression of genes involved 
in the promotion of platelet aggregation, endothelial permeability and inflammations in 
endothelial cells (151). A follow up study performed by this same lab found that 
S100A8/A9 induced apoptotic signaling in endothelial cells through caspase-dependent 
and -independent mechanisms (150).  
S100A8/A9 and Exercise 
Although the exact mechanisms are still under investigation, S100A8 and S100A9 
have known roles in inflammatory disease pathologies. However, the effects of acute and 
chronic exercise on the secretion of these proteins are even less understood. Consistent 
with the inflammatory response to tissue injury, elevated plasma S100A8/A9 have been 
reported in response to high intensity or high volume exercise compared to resting levels 
(30). Substantial increases in circulating S100A8/A9 were observed after completion of a 
marathon (~96-fold), half marathon (~13 fold), 30-km run (~20-fold), multi-day military 
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ranger course corresponding to 35% VO2max (~8 fold), and a VO2max test (~3 fold). 
This may be indicative of damage to the vascular endothelium caused by the stress of 
exercise resulting in microthrombi and subsequent activation of myeloid cells (30). These 
authors estimate the half-life of S100A8/A9 to be ~5 hrs following exercise. However, 
the participants in this study were all younger adults free of CVD, and thus further 
investigations into levels of S100A8/A9 in disease states associated with chronic 
inflammation are needed to fully understand the half-life of these proteins in other 
biological conditions. 
Indeed, it appears that S100A8/A9 are playing a key role in the exercise-induced 
inflammatory response. Similar to the study by Fagerhol et al., another lab found a 6-fold 
increase in serum S100A8/A9 after a marathon run with levels remaining elevated for 
three hours after completion of the run and returning to resting levels after 24 hrs (111). 
Creatine kinase (CK) and C-reactive protein (CRP) levels in these marathon runners 
increased after completion of the run with the peak values occurring 24 hours after the 
run. Exercise intensity was also assessed, with an immediate increase in S100A8/A9 
serum levels noted after a strenuous, but not after a moderate intensity exercise, followed 
by a significant increase in S100A8/A9 and CK concentrations in both groups one hour 
after the completion of exercise (111). Additionally, these authors found that eccentric 
exercise (downhill running), compared to concentric exercise, resulted in elevated serum 
S100A8/A9 even after 24 hrs and that this corresponded with elevated CK levels. These 
observed increases in S100A8/A9 following exercise were accompanied by increases in 
other inflammatory factors such as IL-6 and TNF-α, suggesting that S100A8/A9 are 
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likely involved in an acute phase response immune system reaction that stimulates later 
increases in CRP (111). 
Interestingly, marathon-induced increases in S100A8/A9 were 1.5-fold greater in 
highly trained individuals compared to their lower-fit counterparts, despite no differences 
in CK or CRP levels as a function of training status (111). This is contrary to other 
findings of a blunted exercise-associated stress response as a result of upregulated 
defense mechanisms in trained vs. untrained individuals. This response may also be 
tissue-specific, as we have found higher levels of S100A9 in the secretome of inactive 
individuals’ CD34-/CD31+ CACs compared to that of endurance-trained individuals 
(88), although the levels in that particular study were cross-sectional in nature and 
assessed at rest without the added stimulus of exercise. 
Mortensen et al. (2014) identified skeletal muscle as another source of 
S100A8/A9 during exercise. Three hours of cycle ergometer exercise at 60% VO2max 
upregulated S100A8 and S100A9 mRNA levels in human skeletal muscle by 5-fold and 3 
hours of two-legged dynamic knee extensor exercise at 50% peak power output increased 
arterial plasma S100A8/A9 concentrations by 2-fold (113). This is the first study to note 
S100A8/A9 being released from skeletal muscle. The purpose of S100A8/A9 secretion 
from skeletal muscle or other tissues as a result of exercise is currently unknown. As 
there is a close relationship between activated inflammatory cells and circulating 
S100A8/A9, it has been suggested that it plays a role in the acute phase immune response 
associated with exercise (111, 113). Some authors speculate that it may serve a protective 
role against certain cancers, as S100A8/A9 have been found to induce apoptosis of tumor 
cell lines (113). Thus, it is possible that these proteins are serving to mediate both 
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beneficial and detrimental effects of exercise on health. Of note, these studies 
investigating the effects of exercise on S100A8/A9 do so after extreme bouts of exercise. 
These levels far exceed what the average person performs on a daily basis, or what is 
recommended by the American College of Sports Medicine (ACSM) (107). Additionally, 
investigations into the secretion of S100A8/A9 from different tissues and/or myeloid 
cells as a function of exercise are minimal. As such, it is evident that more research is 
needed to understand the role of S100A8/A9 in exercise, health and disease. 
 
Summary 
 One in every 4 deaths in the Unites States each year is caused by CVDs (45). As 
discussed above, traditional CV risk factors such as dyslipidemia, hypertension and 
diabetes account for only a fraction of events related to CVDs (112), emphasizing the 
need for investigations into more novel risk factors. Since the late 1990s, CACs have 
been identified as potential factors that may help account for some of these events as 
lower CAC number has been found to serve as a predictor of CV risk (7, 8, 47). Since 
then, many studies have investigated cell number as novel CV risk factor. 
Although CAC is a broad term including any circulating cell with angiogenic 
potential, our lab has focused on isolating specific cells through surface markers in order 
to isolate a more defined population with known roles in angiogenesis. Several CAC 
subtypes have been used in experimental and/or clinical trials to examine the use of 
CACs in autologous cell transplants in the treatment of ischemic CVDs. Although 
promising in animal studies, these trials in humans have been met with mixed results (97, 
120, 121, 143, 144). Collectively, the research in the CAC field has identified discordant 
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findings in the use of CACs for therapies in human ischemic CVDs. Many believe this is 
a result of the autologous nature of these cells such that CACs from unhealthy individuals 
are being isolated, purified and re-introduced to the ischemic tissue of the donor. It is 
now understood that CACs from patient populations do not function as well as those from 
healthy individuals (76). As such, an emphasis has been placed on ways to enhance the 
functional capacity of CACs to be used for autologous cell therapies in order to improve 
the outcomes of this treatment (13, 58, 102).  
As discussed above, endurance exercise training has been found to improve both 
CAC number and function. We have found that paracrine function of CACs is altered as a 
result of habitual endurance exercise, with secreted factors from inactive individuals 
exhibiting lower angiogenic capacity compared to endurance-trained individuals. These 
findings and other research supporting the theory that aerobically fit individuals have 
higher functioning cells have led us to use CACs from this population as a model of 
optimal CAC function and means of comparison when studying CACs from CVD 
patients. As it is now generally accepted that CACs function predominantly through 
paracrine actions, it is critical to understand the factors being secreted by CACs as a 
function of health and fitness status that may help or hinder angiogenesis if autologous 
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Chapter 3:  Chronic endurance exercise affects paracrine action of CD31+ and 
CD34+ cells on endothelial tube formation 
The following article was published in the American Journal of Physiology, Heart and 
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ABSTRACT 
We aimed to determine if chronic endurance exercise habits affected redox status 
and paracrine function of CD34+ and CD34-/CD31+ circulating angiogenic cells 
(CACs). Subjects were healthy, nonsmoking, men and women aged 18-35 yrs and 
categorized by chronic physical activity habits. Blood was drawn from each subject for 
isolation and culture of CD34+ and CD34-/CD31+ CACs. No differences in redox status 
were found in any group across either cell type. Conditioned media (CM) was generated 
from the cultured CACs and used in an in vitro HUVEC-based tube assay. CM from 
CD34+ cells from inactive individuals resulted in tube structures that were 29% shorter in 
length (P<0.05) and 45% less complex (P<0.05) than the endurance-trained group. 
CD34-/CD31+ CM from inactive subjects resulted in tube structures that were 26% 
shorter length (P<0.05) and 42% less complex (P<0.05) than endurance-trained 
individuals. Proteomics analyses identified S100A8 and S100A9 in the CM. S100A9 
levels were 103% higher (P<0.05) and S100A8 was 97% higher in the CD34-/CD31+ 
CM of inactive subjects compared to their endurance-trained counterparts with no 
significant differences in either protein in the CM of CD34+ CACs as a function of 
training status. Recombinant S100A8/A9 treatment at concentrations detected in inactive 
subjects’ CD34-/CD31+ CAC CM also reduced tube formation (P<0.05). These findings 
are the first, to our knowledge, to demonstrate a differential paracrine role in CD34+ and 
CD34-/CD31+ CACs on tube formation as a function of chronic physical activity habits 
and identifies a differential secretion of S100A9 by CD34-/CD31+ CACs due to habitual 
exercise.  
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INTRODUCTION  
Cardiovascular disease (CVD) and the associated dysfunction of the vasculature is 
the leading cause of death in the developed countries (45). Studies suggest that the repair 
and maintenance of the vascular endothelium is critically dependent on the number and 
function of circulating angiogenic cells (CACs) (4, 147, 172). CAC is a broad term for 
subgroups of peripheral blood mononuclear cells with angiogenic properties that 
stimulate vascular repair and contribute to neovascularization. CD34 is the most 
commonly described cell surface marker on CACs that are known for their progenitor 
cell properties (103). CD31 is a cell surface marker most commonly found in mature 
endothelial cells, but has also been identified in circulating cells with angiogenic 
properties (64, 75, 76, 78, 84). Although not as commonly studied as CD34+ CACs for 
therapeutic neovascularization, CD34-/CD31+ CACs have been found to exhibit similar 
angiogenic potential as CD34+ CACs in terms of improving mouse hind-limb ischemia, 
emphasizing the importance of studying non-progenitor cell lines which may also be 
involved in angiogenesis (78). Indeed, cells characterized by both markers have been 
previously found to exhibit angiogenic characteristics in vitro (4, 53, 75, 125) and in vivo 
(79, 95, 103).  
Originally believed to exert their reparative functions through direct incorporation 
into the endothelium (4), recent evidence indicates that CACs accomplish their pro-
angiogenic effects through paracrine mechanisms. Specifically, CACs are thought to 
secrete factors that elicit actions on the pre-existing endothelium and/or signal other 
circulating cells to home to the endothelium (79, 81, 125, 145, 175). Recently, Hynes et 
al. (2011) demonstrated that secretome from cultured CACs successfully treated a 
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porcine model of myocardial infarction, suggesting that paracrine factors secreted by 
CACs may be more important for vascular repair than the cells alone (54). Urbich et al. 
found that CACs expressed and released a number of different factors that assist with the 
growth of mature endothelial cells to accelerate revascularization in ischemic tissues 
(145). However, CD34+ or CD34-/CD31+ CAC paracrine actions and their susceptibility 
to modulation by lifestyle factors (e.g., physical activity) have received minimal 
investigation.  
Physical activity is associated with improvements in CV health, including 
attenuation of many classic CVD risk factors (65, 98) and improvements in endothelial 
function (22, 133). Our lab and others have previously shown that endurance exercise 
training increases CAC number and enhances intracellular redox balance in younger and 
older adults compared to their sedentary counterparts (63, 66, 94, 146-148, 166). Hoetzer 
et al (2007) found that migratory activity of sedentary individuals’ CACs improved by 
~50% after 12 weeks of exercise training(50). We previously documented that CACs 
from young sedentary but otherwise healthy individuals exhibit an unfavorable balance 
between reactive oxygen species (ROS) and nitric oxide (NO) compared to their 
endurance-trained counterparts (63, 66). It is generally accepted that CACs with less than 
optimal function cannot contribute properly to vascular repair or neoangiogenesis, thus 
hindering their therapeutic use (35). 
 Previous studies have examined the effects of endurance exercise habits on CAC 
function through measures such as migration and adhesion (50, 146), but the paracrine 
function of CD34+ and CD34-/CD31+ CACs on angiogenesis has not been considered. 
The purpose of this study was to determine whether there is a differential response in 
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paracrine function of CD34+ and CD34-/CD31+ CACs as a result of chronic endurance 
exercise habits in younger men and women and to identify differences in CAC 
intracellular redox pathways that may be eliciting angiogenic or anti-angiogenic actions. 
We hypothesized that both CD34+ and CD34-/CD31+ CACs from endurance-trained 
individuals will have enhanced paracrine function that will result in superior angiogenic 
capacity compared to inactive individuals and that this will be linked to a healthier redox 
balance in the endurance-trained group. A secondary aim of our study was to identify 
proteins present in the secretome of CD34+ and CD34-/CD31+ CACs and to determine 
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METHODS 
Ethical Approval 
The University of Maryland College Park Institutional Review Board approved all 
study procedures and subjects provided written informed consent. The study procedures 
conformed to the standards set by the Declaration of Helsinki. 
Screening 
Subjects in this study were healthy, nonsmoking, men and women aged 18-35 yrs 
with no history of CV or metabolic disease. Potential subjects were initially screened by 
telephone or email, and reported to the laboratory following an overnight fast for a 
screening visit to verify eligibility. Subjects were categorized based on their reported 
physical activity over the last 5 years and confirmed via VO2max. Specifically, inactive 
subjects (n=12; 5 women and 7 men) reported performing ≤20 min endurance exercise on 
≤2 days/week. The active group (n=15, 5 women and 10 men) reported performing ~4 
hours/week of low to moderate intensity activity and the endurance-trained group (n=14, 
9 women and 5 men) reported performing >4 hours/week of moderate to high intensity 
endurance exercise. Groups were matched for age and body mass index (BMI). Exclusion 
criteria were as follows: systolic blood pressure ≥130 mm Hg, diastolic blood pressure 
≥90 mm Hg, serum total cholesterol ≥200 mg/dl; low-density lipoprotein-cholesterol 
≥130 mg/dl; high-density lipoprotein-cholesterol ≤ 35 mg/dl; fasting glucose ≥100 mg/dl. 
Women were all tested during the early follicular phase of their menstrual cycle.  
Maximal Graded Exercise Test, Body Composition and Blood Sampling 
A screening blood sample was obtained for assessment of fasting serum 
triglyceride (TG), lipoprotein lipids, and glucose (Quest Diagnostics, Baltimore, MD). 
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Height, weight, seated blood pressure and BMI were measured, and body composition 
was assessed using the 7-site skinfold procedure (62). Maximal oxygen consumption 
(VO2max) was assessed using a constant-speed treadmill protocol with 2–3% increases in 
incline every 2 min until exhaustion. The treadmill speed was based on the subject’s 
experience, typical run speed, and heart rate such that VO2max was achieved within 6–12 
min. Pulmonary ventilation and expired gas concentrations were analyzed in real time 
using an automated computerized indirect calorimetry system (Oxycon Pro, Viasys). VO2 
was considered maximum if a plateau was achieved (increase in VO2 of < 250 ml/min 
with increased work rate). In the absence of a clear plateau, tests had to meet at least two 
of the following secondary criteria: a respiratory exchange ratio > 1.10, a rating of 
perceived exertion >18, and a peak heart rate within 10 beats/min of the age-predicted 
maximum. On the testing day for blood sampling for CACs, the subjects reported to the 
laboratory in the morning after an overnight (~12 hr) fast. Endurance-trained and active 
subjects performed their normal exercise routine 16-24 hours prior to the blood sampling. 
A sample of 50mL of blood was drawn using EDTA-tubes (Becton Dickinson) for 
isolation of CD34+ and CD34-/CD31+ CACs.  
Immunomagnetic Cell Separation 
Peripheral blood mononuclear cells (PBMCs) were isolated from the venous 
blood samples using density gradient centrifugation (Ficoll, GE Healthcare). The CD34+ 
fraction was purified using multiple rounds of immunomagnetic cell separation according 
to the manufacturer’s instructions (EasySep® Immunomagnetic Cell Separation Kits, 
STEMCELL Technologies) using an Ab specific for CD34. CD31+ cells were selected 
from the CD34- fraction of cells and purified as described above using and Ab specific 
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for CD31 (hereby referred to as CD34-/CD31+). Multiple flow cytometry analyses in our 
lab have resulted in a CD34+ cell isolation purity of 52 ± 3% in the positively-selected 
fraction (compared to the 0.1% in total PBMCs prior to selection (Figure 3.1A and 3.1B) 
and virtually no detectable CD34+ cells (<0.1%) in the CD34-depleted fraction (Figure 
3.1C). This isolation approach has been published previously by our lab (63, 64) and the 
purity of our isolation is equivalent to or greater than other published results also using 
non-mobilized blood (4, 6, 41, 128, 160). The different surface antigen combinations 
were chosen on the basis of previous research indicating the involvement of 
stem/progenitor (i.e., CD34+), and endothelial antigen-expressing (i.e. CD31+) PBMC 
subsets originating from bone marrow or the vessel wall in the maintenance and repair of 
the vascular endothelium (6, 23, 41, 75, 79, 128).  
CAC Culture, Conditioned Media, and Angiogenesis Assay 
CD34+ and CD34-/CD31+ CACs were re-suspended in un-supplemented 
endothelial growth medium free of growth factors or serum, (EBM-2, Lonza) with 1% 
Antibiotic-Antimycotic (Invitrogen) each at a density of 100,000 cells per well. Cultures 
were maintained for 48 hrs in a humidified incubator at 37oC and 5% CO2. After 
incubation, the conditioned media (CM) from all wells of the same cell type was 
withdrawn, combined into one tube and clarified by spinning at 2,500xg for 20 min to 
remove cells and debris from the medium. For the angiogenesis tube formation assay (2, 
19, 39, 125), culture plates were coated with Reduced-Growth Factor Matrigel (BD 
Biosciences) and the matrigel was left to solidify for 30 min at 37oC and 5% CO2. Under 
these in vitro conditions, HUVECs will form multi-cell cords, which serve as a global 
indicator of the angiogenic cascade. Each condition was performed in duplicate and each 
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well contained 20,000 human umbilical vein endothelial cells (HUVECs) and equal 
volumes of CM from either CD34+ or CD34-/CD31+ CACs. Control wells were 
prepared with a similar amount of fresh EBM-2. The average HUVEC passage used in 
the angiogenesis assay for endurance-trained, active, and inactive subjects was 4.4±0.4, 
4.6±0.3 and 4.2±0.3, respectively (n.s.). These plates were cultured for 16 hrs at 37oC and 
5% CO2. The cultures were then visualized under a light microscope and 5 random 
images were photographed per well. These images were then coded and blindly assessed 
for HUVEC tube length and complexity (2, 9, 67) by two individuals. Tube length of 
each segment was quantified using ImageJ and averaged over the total number of images. 
Complexity was quantified as the number of nodes present, with a node being a site with 
>3 branching points. Results are presented as each condition normalized to the basal 
(EBM-2) condition to control for daily variability in HUVEC growth and passage number 
with each assay. Average readings of the two individuals were used for statistical 
analyses. 
Measurement of Intracellular NO and ROS 
These experiments were performed on freshly isolated cells in duplicate as we 
have described previously (63, 64), with minor modifications. Briefly, 1.5 × 105 cells 
were stained with 10 µM 4-amino-5-methylamino-2′,7′-difluorofluorescein (DAF-FM) 
diacetate for determination of intracellular NO levels or 2 µM 2´,7´-
dichlorodihydrofluorescein diacetate (H2DCFDA) for determination of intracellular ROS 
levels (Molecular Probes). 4',6-diamidino-2-phenylindole (DAPI; 750 ng/ml) was used to 
identify cell nuclei (Molecular Probes). Cells were incubated with fluorescent dyes in a 
final volume of 150 µl serum-free PBS for 30 min at 37°C. NO and ROS fluorescence 
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were quantified using a fluorescent microplate reader (Biotek) using excitation and 
emission filters of 488 and 535 nm, respectively. DAPI fluorescence was measured using 
excitation and emission filters of 355 and 460 nm, respectively. NO and ROS 
fluorescence values were divided by DAPI fluorescence values to normalize for cell 
number. All fluorescent probes were validated using positive and negative controls as 
described previously by our lab (63, 64). Briefly, we observe several fold increases in 
intracellular H2DCF-DA signal in the presence of 3-Morpholinosydnonimine (200 µM, 
Figure 3.4A). Pretreatment with PEG-catalase (50U/mL) reduces H2DCF-DA signal by 
nearly 40% after exposure to hydrogen peroxide (500 µM, Figure 3.4B). Additionally, we 
observed several fold increases in DAF-FM signal using NO donor, Diethylenetriamine 
NONOate (50 µM, Figure 3.5A) or 3-Morpholinosydnonimine (20 µM, Figure 3.5B) and 
substantial reduction in DAF-FM signal with L-NAME treatment (300 µM, Figure 3.5B). 
Intra-assay coefficients of variation for ROS and NO were 5.4% and 4.8%, respectively.  
Assessment of Gene Expression by RT-PCR 
RNA was extracted from freshly isolated CACs using the TriZol reagent, DNase 
treated using TURBO DNA-free™ Kit (Life Technologies), and reverse transcribed to 
cDNA. Expression of angiogenic [endothelial nitric oxide synthase (eNOS)], and pro-
oxidant [NADPH oxidase subunits gp91phox and p47phox] genes were assessed as 
previously described (66) to confirm our hypothesis that ROS and NO were mediating 
differences in CAC paracrine function. Additional gene targets include S100A8 (Forward 
primer: 5’-AGCCCTGCATGTCTCTTGTC-3’, Reverse primer: 5’-
ACGTCTGCACCCTTTTTCCT-3’) and S100A9 (Forward primer: 5’-
TCATCATGCTGATGGCGAGG-3’, Reverse primer: 5’-
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CCTGGCCTCCTGATTAGTGG-3’), which were assessed to confirm that each CAC 
subtype expressed the mRNA to produce the S100A8 and S100A9 proteins identified in 
our CM.  
Mass Spectrometry, Western Blot Analysis and S100A8 and S100A9 Expression 
Previously clarified CM from CD34+ and CD34-/CD31+ cells was divided into 
aliquots and stored at -80oC until further analyses. Proteomics techniques were used to 
determine proteins present in the CD34+ and CD34-/CD31+ CM from of each 
endurance-trained and inactive groups. Spectral counts for n=1 per group were used as an 
initial non-labeled method providing semi-quantitative data (99). Subsequently, these 
findings were quantitatively confirmed using immunoblotting analyses on n=12 per 
group. Media was concentrated using Amicon Ultra 0.5 3kD centrifugal filter devices 
(Millipore). The soluble proteins in the supernatant were subjected to digestion with 
trypsin Lys-C. Samples were analyzed using a ThermoFinnigan LTQ Orbitrap XL mass 
spectrometer, and matched to the UniProtKB database. Western blot analyses were used 
to assess differences in two identified S100 proteins with specific antibodies for S100A8 
(R&D Systems) and S100A9 (Santa Cruz Biotech). Membranes were washed and the 
incubated with horseradish peroxidase (HRP)- conjugated anti-mouse IgG (Cell 
Signaling; 1:1000) or HRP-conjugated anti-goat IgG (Novus; 1:5000) secondary 
antibodies. Blots were developed using Super Signal ECL reagents (Thermo Scientific) 
and bands were visualized and quantified using Chemi-Doc Imaging System and 
software (BioRad). Values were normalized to 100,000 cells/well used to generate the 
CM. Recombinant human S100A8/A9 complex (R&D Systems) was used in western 
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blots to establish a standard curve based on concentrations reported in the literature (92, 
151) and to quantitatively assess levels present in the CM of each CAC subtype. 
Recombinant S100A8/A9 treatment  
 To confirm the direct effects of S100A8 and S100A9 on HUVEC tube formation, 
the concentrations and proportions estimated in the CM of the inactive subjects’ CD34-
/CD31+ CACs were used in an angiogenesis assay. As estimated, 7.18 µg/mL of 
recombinant human S100A8 (ProSpec Bio) and 3.06 µg/mL of recombinant human 
S100A9 (Life Technologies) were added to a HUVEC-based tube formation assay and 
compared to the positive control prepared with EBM-2 and vehicle control. In these 
experiments, each condition was assessed in samples collected from six independent cell 
culture wells from multiple culture plates collected on different days. All experiments 
were conducted on cells from the same passage number (P4). As described above, each 
well contained 20,000 HUVECs. The plates were cultured for 16 hrs at 37oC and 5% 
CO2. The cultures were then visualized under a light microscope and 5 random images 
were photographed per well. 
Statistics 
Statistical analyses were completed using IBM SPSS Statistics 21. Assumptions 
of homoscedasticity and normality were verified for all outcome measures. Data were 
analyzed using multivariate ANOVA with pairwise comparisons where appropriate. t-
tests were used for western blot analyses. Statistical significance was accepted at P ≤ 
0.05. Values are expressed as mean ± standard error of the mean. 
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RESULTS 
Subject characteristics (Table 3.1.) 
All subject groups (n= 14 endurance trained, n=15 active and n=12 inactive) were 
of the same age and BMI. Training status was confirmed through VO2max with the 
endurance-trained subjects having 15% greater VO2max compared to active and 40% 
greater VO2max compared to inactive subjects (P<0.05). Active subjects had 30% higher 
VO2max than inactive (P<0.05). Despite the three groups being matched for BMI, 
inactive subjects had significantly higher body fat percentage than both the active and 
endurance-trained subjects (P<0.05). Importantly, subjects were all matched for the 
majority of cardio-metabolic risk factors including systolic blood pressure, glucose, 
cholesterol, TG, and lipoprotein lipids. 
Angiogenic tube formation with conditioned media 
CD34+ cells. Conditioned media (CM) from a purified population of CD34+ 
CACs (Figure 3.1) resulted in 29% lower tube length (P<0.05) and 45% lower 
complexity (P<0.05) in inactive subjects compared to endurance-trained subjects, and 
14% lower length (P<0.05) and 20% lower complexity (P=0.05) in active subjects 
compared to endurance-trained subjects (Figure 3.2A and 3.2B). CD34+ CM from 
inactive subjects produced lower HUVEC length (n.s.) and complexity (P=0.05) than 
CD34+ CM from active subjects (15% and 26%, respectively; Figure 3.2A and 3.2B). 
Representative images from each condition can be found in Figure 3.3. CM from both 
endurance-trained and active subjects CD34+ CACs did not result in statistically different 
tube length or complexity (P>0.05) compared to basal conditions whereas CM from 
inactive individuals CACs resulted in significantly lower length and complexity 
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compared to basal (P<0.05). 
CD34-/CD31+ cells. HUVEC tube length was 26% lower (P<0.05) and 
complexity was 42% lower (P<0.05) with CM from CD34-/CD31+ CACs of inactive 
subjects compared to endurance-trained individuals. CD34-/CD31+ CM from endurance-
trained subjects was not significantly different in terms of tube length and complexity 
than CD34-/CD31+ CM from active subjects (Figure 3.2C and 3.2D). Although not 
statistically significant, CM from CD34-/CD31+ CACs of inactive subjects resulted in 
16% shorter tube length and 28% less complexity than active subjects (Figure 3.2C and 
3.2D). There was no significant effect of sex on tube formation for either CD34+ or 
CD34-/CD31+ CM (P>0.05). Representative images from each condition can be found in 
Figure 3.3. The CD34-/CD31+ CM from endurance-trained and active subjects’ CACs 
did not result in significantly different tube length or complexity (P>0.05) compared to 
basal conditions, whereas CD34-/CD31+ CM from inactive individuals’ CACs caused 
significantly lower length and complexity compared to basal (P<0.05). 
Intracellular ROS and NO 
To determine if the differences in CM-induced tube formation were associated 
with differences in intracellular redox pathways, we assessed intracellular ROS and NO 
levels using previously validated techniques (Figures 3.4A-B and Figure 3.5A-B) and a 
purified population of cells (Figure 3.1). There were no significant differences in 
intracellular ROS levels between endurance trained, active or inactive subjects’ CD34+ 
CACs (Figure 3.4C) or CD34-/CD31+ CACs (Figure 3.4D). In addition, no significant 
differences between intracellular NO levels were detected between CD34+ CACs from 
endurance trained, active and inactive subjects (Figure 3.5C) or CD34-/CD31+ CACs 
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(Figure 3.5D). There was no significant effect of sex on intracellular ROS or NO levels 
for either cell type. 
Gene Expression 
CD34+ cells. There were no significant effects of training status on CD34+ eNOS 
(Figure 3.6A) or p47phox or gp91phox mRNA expression (Figures 3.6B and 3.6C). There 
was no significant effect of sex on expression of any of our genes of interest in CD34+ 
CACs. 
CD34-/CD31+ cells. eNOS gene expression was not statistically different in 
inactive subjects compared to active and endurance-trained subjects (Figure 3.6D). There 
were no significant differences between groups for p47phox or gp91phox gene 
expression in CD34-/CD31+ CACs (Figure 3.6E and 3.6F). There was no significant 
effect of sex on gene expression for any of our targets for CD34-/CD31+ CACs. 
Detection of Proteins in Conditioned Media 
In an attempt to identify secreted paracrine factors from CACs, conditioned 
medium from CD34+ and CD34-/CD31+ cells was analyzed by mass spectrometry. Two 
targets from the S100 family of proteins, S100A8 and S100A9, were identified in the 
secretome of both CD34+ and CD34-/CD31+ cells (Figure 3.7). Due to our detection of 
S100A8 and S100A9 in the CM of each CAC sub-type, we sought to confirm that CACs 
express these genes. S100A8 and S100A9 were expressed in both CAC sub-types (Figure 
3.8). In CD34+ CACs, there were no significant differences between groups in S100A8 
mRNA or S100A9 mRNA (Figure 3.8A and 3.8B). S100A8 and S100A9 mRNA in 
CD34-/CD31+ CACs were also not significantly different as a function of training status 
(Figure 3.8C and 3.8D). 
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The S100A8 and S100A9 proteins are known mainly for their role in 
inflammation but their role in the regulation of angiogenesis is not well understood, 
especially as a secreted factor from our cells of interest. As such, we sought to determine 
if differences existed in the levels of these proteins present in CAC conditioned media as 
a result of chronic exercise training status. Immunoblotting for S100A8 and S100A9 in 
the conditioned media of CD34+ cells did not show significant differences between 
endurance-trained and inactive subjects (Figure 3.9A and 3.9B). There was also no 
significant sex-related difference in the content of either protein in CD34+ CM. In CD34-
/CD31+ cells, there were no significant differences in S100A8 content between 
endurance trained and inactive subjects (P=0.08; Figure 3.9C). However, S100A9 content 
was significantly higher in CD34-/CD31+ conditioned media of inactive subjects 
compared to endurance-trained subjects (P<0.05; Figure 3.9D). There was no significant 
effect of sex on S100A8 or S100A9 content in CM from CD34-/CD31+ CACs. 
Using recombinant human S100A8/A9, a standard curve was established using 
typical concentrations employed in the literature (92, 151) to allow us to estimate total 
content of each protein that the HUVEC cells were exposed to in a subset of remaining 
CM samples (Figure 3.10A). For this experiment, we used n=3 samples from the inactive 
groups’ CD34-/CD31+ CACs to estimate the concentrations of each protein that could 
potentially be responsible for depressed tube formation. As no differences in either 
S100A8 or S100A9 were noted in the CM of CD34+ CACs, we used n=2 inactive CM 
and n=1 endurance trained subjects’ CM to estimate the concentrations of each of these 
proteins. The total amount of S100A8 was estimated to be 8.69±4.3 µg/mL and S100A9 
was estimated to be 16.97±4.6 µg/mL in CD34+ cell CM (Figure 3.10B). CM for CD34-
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/CD31+ CACs contained approximately 7.18±0.28 µg/mL of S100A8 and 3.06±0.95 
µg/mL of S100A9 (Figure 3.10C). We next calculated the proportion of S100A8/S100A9 
and found that CD34+ CM had an A8/A9 ratio of 0.513, while CD34-/CD31+ CM 
contained an A8/A9 ratio of 2.343 (Figure 3.10B and 3.10C).   
Recombinant human S100A8 and S100A8 treatment 
 Recombinant human S100A8 and S100A9 were added to a HUVEC-based tube 
formation assay in the concentrations and proportions that were estimated to be present in 
the CD34-/CD31+ CM of inactive subjects (7.18 µg/mL of S100A8 and 3.06 µg/mL of 
S100A9). Compared to the basal control, addition of S100A8 and S100A9 resulted in an 
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DISCUSSION 
Paracrine actions are believed to be the major mechanism through which CACs 
exert their angiogenic properties on the pre-existing endothelium, but it was previously 
unknown whether regular endurance exercise affected these actions. In this study we 
demonstrate that conditioned media generated from inactive subjects’ CD34+ and CD34-
/CD31+ CACs depresses paracrine-mediated tube formation. These data strongly suggest 
that endurance exercise training-mediated alterations in CAC paracrine activity influence 
angiogenesis. Other studies have demonstrated the role of paracrine signaling of CACs in 
diseased states (54, 125, 174). Our data provide further support for a paracrine role for 
CD34+ and CD34-/CD31+ CACs on angiogenesis in younger, healthy individuals. More 
importantly, to our knowledge, we are the first to report of a differential paracrine role in 
CD34+ and CD34-/CD31+ CACs on HUVEC-based tube formation as a function of 
chronic physical activity habits.  
Based on previous research from our lab (63), we hypothesized that differences in 
intracellular ROS and NO concentrations as a result of exercise-training status would at 
least partially explain our observed differences in paracrine function in both cells types. 
Surprisingly, the present data suggest that intracellular ROS and NO are not playing a 
major role in regulating the differential paracrine responses observed. We found no 
significant effects of training status on intracellular NO or ROS levels or in mRNA 
expression for eNOS as well as p47phox and gp91phox for either cell type. Although some 
studies have found an effect of endurance exercise on improved redox balance in both 
healthy (63, 161) and diseased populations (33, 131, 136), others have found 
improvements in endothelial function with endurance exercise independent of changes in 
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oxidative stress (98). It is important to note that these previous studies have focused 
mainly on endothelial progenitor cells (EPCs), which share some of the same 
characteristics as the two CAC subtypes that we studied, but generally they express both 
the progenitor cell marker (CD34) and the endothelial marker (CD31 or VEGFR2) 
simultaneously and are negative for CD45. As these cells can have very different 
properties, caution must be used when comparing studies using different cell types as a 
result of selection or culture conditions. Importantly, our previous cross-sectional studies 
included only men (63, 66), whereas in the current study we included both men and 
women, potentially accounting for the different findings in the current study compared to 
our previous work. Recently, Guhanarayan et al. (2014) found that 10 days of reduced 
physical activity decreased intracellular NO in CFU-Hill CACs, but they observed no 
differences in intracellular NO levels in freshly isolated CD34+ CACs similar to those 
investigated in the present study (40). Additionally, they found no significant changes in 
NO or ROS-related gene expression with reduced physical activity in either CAC type. 
Together, these data suggest that the effects of intracellular ROS and NO may be specific 
to certain populations of CACs and emphasize the need for future investigations. 
In an attempt to elucidate potential contributors to our observed differences in 
tube formation, we utilized mass spectrometry analyses to assess the secreted protein 
content of the conditioned media. We identified two members of the S100 family of 
calcium-modulated proteins, S100A8 and S100A9, in the secretome of both CD34+ and 
CD34-/CD31+ CACs. Further, we confirmed that both CAC sub-types expressed mRNA 
species specific for both of these proteins, indicating that both cell types possess the 
necessary molecular machinery to produce the proteins. As our observed differences in 
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tube formation appeared to be a graded effect, we focused on the two extreme groups, 
endurance-trained and inactive, for protein analyses of our conditioned media. We found 
that the protein content of S100A9 was twice as high in the CD34-/CD31+ CM of 
inactive subjects compared to their endurance-trained counterparts. These findings are the 
first, to our knowledge, to demonstrate differential secretion of S100A9 by CD34-
/CD31+ CACs as a function of an individual’s exercise-training status. Although not 
significant, S100A8 was also roughly twice as high in the CD34-/CD31+ CM from 
inactive subjects compared to endurance-trained subjects. S100A8 and S100A9 proteins 
are abundantly expressed in both myeloid and vascular cells (5) and are most commonly 
known for their role in regulating inflammatory processes (5, 27, 153). Several studies 
have linked systemic concentrations of the S100A8/S100A9 heterodimer complex to 
CVDs (5) with plasma levels predicting future CV events in middle-aged healthy 
individuals (17, 18). Thus, the higher levels of S100A9 in inactive individuals are 
consistent with these previous findings indicating these proteins as a risk factor for CVD. 
Croce et al. (2009) demonstrated the enhanced stability of these proteins when 
functioning as a heterodimer complex (18). Given the biology of the S100A8/A9 
complex, it is possible that our S100A8 findings in CD34-/CD31+ CM paired with the 
significant differences in S100A9 may be physiologically relevant despite the lack of 
statistical significance.  
In our hands, we found that our CM from both cell types contained less than 20µg 
of S100A8 and S100A9. Most investigations assessing the in vitro effects of S100A8 or 
S100A9 utilize concentrations between 1-200 µg/mL (5, 92, 151). Thus, our CM content 
is on the low end of the established in vitro range of S100A8 or A9 concentrations. 
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Defining the concentrations of S100A8 or A9 is important since previous publications 
have shown concentration dependent effects on angiogenic function (153). In additions, 
both proteins are able to activate signaling in a homodimer, heterodimer or 
heterotetramer form (153), thus adding more complexity to their mechanism of action. 
When the proportion of S100A8/S100A9 was calculated in the CM there was a greater 
proportion of S100A8/S100A9 in the CD34-/CD31+ CM compared to that of the CD34+ 
CM. These results suggest that CM from the different cells types are fundamentally 
different from each other even though both showed similar effects on the HUVEC cells. 
The differences in the ratios of these proteins in the CM of the two different cell types 
may provide one explanation as to why we observed differences in these proteins as a 
function of training status in the CD34-/CD31+ CM but not in the CD34+ CM. This also 
suggests that other secreted factors may better explain our observed differences in CD34+ 
CM-mediated HUVEC tube formation as a function of training status.  
As we found significantly greater levels of S100A8/A9 in the CD34-/CD31+ CM 
of inactive individuals compared to endurance-trained individuals, we sought to 
empirically test the effects of these proteins on HUVEC tube formation. We added 
recombinant human S100A8 and S100A9 using the estimated concentrations of each of 
these proteins that were present in the CM of CD34-/CD31+ CACs. We found that 
HUVEC length was approximately 18% lower and complexity was 28% lower in this 
condition compared to the positive control. Importantly, these findings confirm the role 
of each of S100A8 and S100A9 in the discovered concentrations as a depressor of 
HUVEC tube formation. 
As only a small percent of the population are high-level endurance athletes, a 
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strength of our study is the inclusion of a regularly active group that met the guidelines 
for physical activity without being defined as “highly trained” or “elite” as this group is 
more applicable to the general population (107). In the current study, we observed a 
graded effect of exercise with CM from endurance-trained athletes contributing best to 
tube formation and CM from inactive subjects having a negative effect on tube formation. 
We observed no significant differences in tube formation between the active and 
endurance-trained groups in the CD34-/CD31+ CM conditions suggesting that the range 
of physical activity influences the function of the CACs. In this study, we only examined 
levels of S100A8 and S100A9 in the CM from the two extreme groups, so future studies 
should also follow up on habitually physically active individuals to determine the 
concentrations on these proteins being secreted by their CACs.  
This study is also unique in that it includes data from both young men and 
women. We did not detect significant differences between any variable measured due to 
sex although we acknowledge that with such a small sample of women the ability to 
detect statistically significant differences is low. Regardless, very little research in the 
CAC field focuses on pre-menopausal women, possibly due to the difficulty controlling 
for menstrual cycle status, as estrogen and other female sex hormones have known effects 
on CAC function (59, 60, 104). In our study, we attempted to control for the effects of 
estrogen throughout the menstrual cycle by testing all women during the follicular phase 
when estrogen is typically at its lowest levels (140). We acknowledge that there are 
individual fluctuations in estrogen levels throughout the menstrual cycle, and we did not 
directly measure estrogen levels, which could have contributed to variations in some of 
our findings. It is also important to mention that our subject groups were heterogeneous 
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with respect to representation of men and women, with the endurance-trained groups 
being comprised of proportionally more women compared to the other groups.  However, 
we do feel that it is an important contribution to the literature to include this population 
both as a comparison to men and to begin to learn more about the health and function of 
CACs from pre-menopausal women. 
Various sub-populations of CACs have been used in autologous cell therapies as a 
means for treating ischemic CVD. It is now well accepted, and our results support, that 
CACs work through paracrine functions (38, 78, 126, 160). A sedentary lifestyle is 
associated with future CVD risk through diseases such as obesity and Type II Diabetes. 
In the absence of lifestyle changes, it is possible that differences in the secretion of these 
proteins in sedentary but otherwise young, healthy individuals will become more 
exacerbated with age and progression of CVD. As such, our findings of greater S100A8 
and A9 secretion by CD34-/CD31+ CACs of young, inactive individuals provide 
rationale for future studies to determine whether the dysfunctional properties of CACs 
from CVD patients are linked to altered S100A8 and A9 secretion.  
Limitations 
We were limited in the number of functional assays that we could perform due to 
the low overall amount of CM that was generated from our isolated cells. Due to this 
limitation, we performed an in vitro assay that has been widely used as a global readout 
of the entire angiogenesis cascade. We acknowledge that the use of the HUVEC-based 
angiogenesis tube formation assay does not individually assess all the critical regulatory 
steps during angiogenesis. Future studies should include measures such as HUVEC 
proliferation and migration as a complement to the angiogenesis assay to more 
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comprehensively assess angiogenic activity in endothelial cells. Additionally, further 
research on the different proportions of S100A8 and S100A9 as a function of training 
status would provide more understanding into function of these proteins. In the current 
study we used recombinant S100A8 and S100A9 to reproduce the depressed tube 
formation observed when using CD34-/CD31+ CM from inactive subject’s CACs. We 
acknowledge that other secreted factors are potentially contributing to our observations. 
Future experiments should employ a loss of function approach to confirm that S100A8 
and S100A9 are mediating the differences in tube formation or determine whether other 
secreted proteins present in the CM are affecting HUVEC function as well. Neutrophils 
and other myeloid cells are major producers of S100A8 and S100A9. Our CAC isolations 
yield a purity of approximately 50% and therefore, we cannot exclude the possibility of 
other cells contributing to the levels of S100A8 and S100A9 in our CM. It is unlikely that 
one individual cell type would make up the majority of the other 50% consistently across 
training groups. Rather, this is more likely comprised of a heterogeneous mix of cell 
types. As such, it is probable that the differences observed in our study are predominantly 
due to each of the purified CAC subtypes, although further characterization of other cell 
types present after CAC purification are necessary to confirm this. Furthermore, rates of 
cell proliferation over the culture period among different training groups should be 
considered in future work to confirm that the observed differences are due to greater 
secretion of S100A8 and S100A9 and not a greater number of cells. 
All measures in this study were taken under basal cell conditions, which is not 
always representative of the in vivo environment. Under resting conditions these cells are 
less active and many studies have found that pharmacological challenges such as LPS or 
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PMA stimulate cytokine/growth factor secretion from various cell types (101). We have 
previously shown that in vivo consumption of a high fat meal alters the intracellular ROS 
levels of CACs (64); thus it is our belief that a similar stimulation may also alter the 
paracrine profile of CACs. Follow-up experiments investigating how an in vivo or in vitro 
challenge affect CAC paracrine functions will be necessary to fully elucidate the 
paracrine and autocrine behaviors of these cells. 
Conclusions 
In summary, we demonstrate, for the first time, a differential effect on tube 
formation when HUVECs were cultured with CM from either CD34+ or CD34-/31+ 
CACs of endurance-trained athletes, active or inactive individuals. CM from inactive 
subject’s CACs appears to produce an inflammatory effect that depresses tube formation 
and this effect is not evident with increased chronic exercise behaviors. We found that 
pro-inflammatory S100A9 secreted by CD34-/CD31+ CACs is significantly higher in the 
CM of inactive individuals compared to their endurance-trained counterparts and culture 
with recombinant S100A8 and S100A9 in concentrations estimated to be present in the 
CD34-/CD31+ CM significantly reduced HUVEC tube formation. These results support 
the possibility that increases in secreted S100A8/A9 in inactive individuals are 
contributing to the reduced HUVEC tube formation associated with CM from CD34-
/CD31+ CACs.  
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Table 3.1. Subject Characteristics 
  Endurance 
Trained (n=14) 
Active (n=15) Inactive (n=12) 
Age (yr) 30±1.5 30±1.3 28±1.4 
BMI (kg/m2) 22±0.6 23±0.5 23±0.6 
Body Fat (%) 12.3±1.8 13.4±1.5 19.7±1.7*# 
Absolute VO2max 
(mL/min) 
3941±264 3599±219 2536±250*# 
Relative VO2max 
(ml/kg/min) 
62±2.1 53.1±1.7* 37±2*# 
SBP (mm Hg) 115±3.6 120±3 122±3.4 
DBP (mm Hg) 70±2 75±1.6* 79±1.8* 
MAP (mm Hg) 85±2.2 90±1.8 93±2.1* 
Glucose (mg/dl) 81±2.8 83±2.3 83±2.7 
Cholesterol (mg/dl) 172±8.6 177±7.2 167±8 
HDL-C (mg/dl) 68±5.6 66±4.6 56±5.3 
LDL-C (mg/dl) 90±7 96.7±5.8 98.4±6.7 
VLDL-C (mg/dl) 14±1.7 14±1.4 13±1.7 
TC/HDL 2.6±0.2 2.8±0.2 3.1±0.2 
LDL/HDL 1.4±0.2 1.6±0.2 1.9±0.2 
Triglycerides (mg/dl) 71±8.8 71±7.3 68±8.3 
















Total PMBCs CD34+ selected PBMCs Unselected CD34- PBMCs 
Figure 1. 
A B C 
Figure 3.1 
Figure 3.1. Flow activated cell sorting (FACS) plots representing PE-conjugated 
CD34/V450-conjugated CD45 cells within (A) total PMBCs, (B) CD34+ selected 
PBMCs using immunomagnetic cell separation procedures and (C) unselected 
(negative fraction) CD34 cells. Multiple trials have resulted in an isolation purity of 52 
± 3%. 
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Figure 2.


























































































































Figure 3.2. Quantification of HUVEC length and complexity after culture with 
conditioned media from CD34+ (A, B) and CD34-/CD31+ cells (C, D). CD34+ and 
CD34-/CD31+ CACs were cultured in un-supplemented endothelial growth medium 
free of growth factors or serum, each at a density of 100,000 cells per well of a 
fibronectin coated plate. Media was collected after 48hrs of culture from each cell 
type. Results are presented as each condition normalized to the basal (EBM-2) 
condition to control for daily variability in HUVEC growth and passage number with 
each assay. Images were taken under 10x magnification. * Indicates statistically 
significant difference from high endurance trained subjects, # Indicates statistically 
significant difference from active subjects. Significance accepted at P ≤ 0.05. 
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Figure 3.3. Representative images of HUVEC cord formation from conditioned media 
of endurance trained (A, D), active (B, E) and inactive (C, F) circulating angiogenic 
cells from CD34+ (A, B, C) and CD34-/CD31+ cells (D, E, F).  
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Figure 4.
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Figure 3.4. Experiments demonstrating the efficacy of the fluorescent probe H2DCF-
DA to detect differences in intracellular ROS in CD34+ PBMCs (A-B, n=3 per 
experiment). In the presence of peroxynitrite donor SIN-1 (200 µM), H2DCF-DA 
signal increases by more than 200% (A). The H2DCF-DA signal is increased by over 
100% in the presence of hydrogen peroxide (500 µM) but pretreatment with PEG-
catalase (50 U/mL) reduces this signal by nearly 40% (B). Effects of exercise training 
status on intracellular reactive oxygen species content in freshly isolated CD34+ (C) 
and CD34-/CD31+ (D) circulating angiogenic cells (n=12 endurance-trained, n=15 
active, and n=12 inactive). 
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Figure 5.




























































































































Figure 3.5. Experiments demonstrating the efficacy of the fluorescent probe DAF-FM 
diacetate to detect differences in intracellular NO in CD34+ and fractioned PBMCs 
(n=3 per experiment). Greater than 700% increases in DAF-FM signal in the presence 
of an NO donor, Deta NONOate (50 µM) (A). Over 3-fold increases in DAF-FM 
signal in the presence of SIN-1 (20 µM), and 56% reduction in DAF-FM signal with 
L-NAME treatment (300 µM) compared to control (B). Effects of exercise training 
status on intracellular nitric oxide content in freshly isolated CD34+ (C) and CD34-
/CD31+ (D) circulating angiogenic cells (n=12 endurance-trained, n=15 active, and 
n=12 inactive). 
	  





































































































































Figure 3.6. Effects of exercise training status on eNOS, p47phox, and gp91phox mRNA 
expression for freshly isolated CD34+ circulating angiogenic cells (A-C; n= 13 
endurance-trained, n=13 active and n=8 inactive), and CD34-/CD31+ circulating 
angiogenic cells (D-F; n=14 endurance-trained, n=15 active and n=11 inactive).  
	  










































































S100A8  10 kDa 
S100A9  14 kDa 
Figure 3.7 
Figure 3.7. Total protein gel of CM from cultured CACs (A) showing bands at 10 
kDa (S100A8) and 14 kDa (S100A9). Semi-quantitative analysis of S100A8 and 
S100A9 in conditioned media of cultured CD34+ cells (B) and CD34-/CD31+ cells 
(C) using mass spectrometry spectrum counts (n=1) to identify proteins present in 
conditioned medium. 
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Figure 8.

































































































Figure 3.8. Effects of exercise training status on S100A8 and S100A9 mRNA 
expression for freshly isolated CD34+ circulating angiogenic cells (A-B; n= 13 
endurance-trained, n=13 active and n=8 inactive) and CD34-/CD31+ circulating 
angiogenic cells (C-D; n=14 endurance-trained, n=15 active and n=11 inactive).  
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Figure 9.















































































Figure 3.9. Secreted S100A8 and S100A9 protein content in cultured CD34+ (A, B) 
and CD34-/CD31+ (C, D) cell conditioned media (CM) from endurance-trained and 
inactive subjects (n=12 per group in CD34+ blots and n=11 per group in CD34-
/CD31+ blots). Values were normalized to cell number (100,000 cells/well) as equal 
volumes of CM were loaded for western blot analysis. Representative blots for CD34+ 
CM (E) and CD34-/CD31+ CM (F). * Indicates statistically significant from 
endurance-trained subjects. Significance accepted at P ≤ 0.05. 
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Figure 3.10 
Figure 3.10. Representative western blots depicting the standard curve (1ug/mL-
300ug/mL) of recombinant human S100A8/A9 used to estimate the approximate 
concentrations of each protein in the CD34+ CM and CD34-/CD31+ CM (A). 
Approximate concentrations of S100A8 and S100A9 present in n=3 CD34+ CM 
samples (n=2 inactive subject CM and n=1 endurance-trained subjects’ CM) (B) and 
n=3 CD34-/CD31+ CM (n=2 inactive subject CM and n=1 endurance-trained 
subject’s CM) (C) as estimated through western blots using this standard curve. 
	  






















































Basal (EBM-2) Condition EBM-2 + Vehicle rhS100A8/S100A9 
Figure 3.11 
Figure 3.11. Effects of recombinant human S100A8 and S100A9 (7.18 µg/mL and 
3.06 µg/mL, respectively for a total volume of 150 µL/well) on HUVEC cord length 
(A) and complexity (B) compared to basal media and vehicle conditions and 
representative images from each (C). In these experiments, each condition was 
assessed in samples collected from six independent cell culture wells from multiple 
culture plates collected on different days. All experiments were conducted on cells 
from the same passage number (P4). * Indicates statistically significant from 
endurance-trained subjects. Significance accepted at P ≤ 0.05. 
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Chapter 4: Paracrine actions of NSTEMI patients’ CD34-/CD31+ CACs impair 
HUVEC tube formation and are mediated by TLR4 
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ABSTRACT 
We sought to determine if conditioned media (CM) from CD34-/CD31+ 
circulating angiogenic cells (CACs) of non ST-segment elevation myocardial infarction 
(NSTEMI) patients results in impaired tube formation and whether pre-treatment of 
human umbilical vein endothelial cells (HUVECs) with inhibitors for receptors of 
S100A8/A9 improves tube formation to levels similar to those observed when using CM 
from endurance-trained athletes. Fasting blood was drawn from 10 athletes aged 18-35 
yrs and 10 NSTEMI patients aged 50-85 yrs for isolation and culture of CACs. CM from 
cultured CACs was used in an angiogenesis assay with and without pretreatment with 
TAK-242, a TLR4 inhibitor, or FPS-ZM1, a RAGE antagonist. CM derived from 
NSTEMI patient CACs resulted in 9% lower tube length (P<0.05) and 18% fewer nodes 
(P=0.08) compared to CM from athletes. Pre-treatment with TAK-242, but not FPS-ZM1, 
improved tube length (P<0.05), number of branches (P<0.05) and number of meshes 
(P<0.05) in the NSTEMI patients compared to CM alone but did not affect tube 
formation in the athletes’ CM conditions (P>0.05). mRNA expression and S100A8 and 
S100A9 content in CM was higher in the NSTEMI patients’ CACs compared to the 
athletes (P<0.05). Recombinant S100A8/A9 experiments also reduced tube formation and 
this effect was rescued with TAK-242 treatment (P<0.05). Flow cytometry analyses 
suggest that CACs from NSTEMI patients contain fewer T-cell and monocyte markers 
compared to athletes (n.s.). These results suggest that S100A8 and S100A9 present in 
CM from CACs of NSTEMI patients impair HUVEC tube formation and that these 
effects appear to be mediated through TLR4. 
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INTRODUCTION 
Circulating angiogenic cells (CACs) are involved in the repair and maintenance of 
the vascular endothelium. Originally believed to incorporate directly into the endothelium 
(4), it is now generally accepted that CACs function mainly through paracrine 
mechanisms (79, 175). A study recently published by our lab found that conditioned 
medium (CM) from CD34-/CD31+ CACs of physically inactive but otherwise healthy, 
younger adults impaired human umbilical vein endothelial cell (HUVEC) tube formation 
compared to their endurance exercise trained or recreationally active counterparts (88). 
We identified higher S100A8 and S100A9 content in the CM generated from CACs from 
inactive individuals’ compared to endurance-trained subjects, and found that these 
proteins were, at least partially, mediating the observed differences in tube formation 
(88). S100A8 and S100A8 are members of the S100 family of calcium binding proteins 
that are well known for their roles in inflammatory diseases (5, 17, 18, 153). They can 
function independently as monomers or as an S100A8/A9 heterodimer complex (153). 
High plasma levels of these proteins have been recently identified as risk factors for 
cardiovascular disease (CVD) (5, 17) with plasma levels predicting future CV events in 
middle-aged healthy individuals (17, 18). However, the direct effects of S100A8 and 
S100A9 secreted by CACs on endothelial cells are less understood.  
CD31 (aka PECAM-1) is a cell surface marker found on circulating endothelial 
cells, neutrophils, monocytes, haematopoietic progenitor cells, T cells, and B cells as well 
as other subsets of cells (76). CD31+ cells have known roles in angiogenesis and CD34-
/CD31+ CACs have comparable, if not greater, angiogenic potential than the more 
commonly studied progenitor cell lines (78). In addition to their higher frequency in 
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peripheral blood, previous work from our lab indicates that CD34-/CD31+ CACs are 
potentially more susceptible to modulation by lifestyle factors than CD34+ CACs (64, 
88). 
It is recognized that the CACs from CVD patients are lower in number and have 
diminished function compared to those from their healthy counterparts (76). Indeed, Kim 
et al. (2014) recently demonstrated that CD31+ CACs from coronary artery disease 
(CAD) patients exhibited lower cell migration rates, lower adhesion, and lower tube 
formation when co-cultured with HUVECs, and showed greater apoptosis compared to 
the CD31+ CACs from healthy controls (76). Additionally, this study found that the 
CD31+ CACs from CAD patients exhibited lower levels of angiogenic T-cell surface 
markers and higher levels of monocyte/macrophage markers (76) as well as an 
upregulation of inflammatory genes and downregulation of angiogenic genes compared 
to healthy subjects. This study highlights the importance of considering the functional 
capacity of CACs to be used for autologous cell therapy.  
Additionally, although other functional traits of CD31+ CACs have been studied 
in CVD populations (76), differential secretion of soluble factors, specifically S100A8 
and S100A9, have not yet been explored in patient populations. The purpose of this study 
is to determine if CM derived from CD34-/CD31+ CACs of non ST-segment elevation 
myocardial infarction (NSTEMI) patients results in impaired tube formation due to 
higher levels of S100A8 and S100A9 when compared to a healthy endurance-exercise 
trained population. The major receptors for S100A8 and S100A9 are toll-like receptor 4 
(TLR4) (155) and the receptor for advanced glycation end products (RAGE) (11), both of 
which are present on HUVECs and have been found to activate downstream 
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inflammatory pathways upon S100A8 and S100A9 binding (26, 155, 162). Thus, we 
aimed to test whether pre-treatment of HUVECs with inhibitors for these major receptors 
of S100A8/A9 will improve tube formation to levels similar to those observed when 
using CM from endurance-trained athletes. Finally, we sought to characterize other 
surface markers present on CD34-/CD31+ CACs from each group to help explain 
potential differences in functional properties between NSTEMI patients’ and healthy 

















104	   	  
METHODS 
Ethical Approval 
The University of Maryland College Park Institutional Review Board approved all 
study procedures and subjects provided written informed consent. The study procedures 
conformed to the standards set by the Declaration of Helsinki. 
Screening 
Potential NSTEMI patients were recruited from patients admitted to the Baltimore 
Veterans Affairs Medical Center. The patients participating in this study were men 50-88 
yrs of age with a BMI between 18-40 kg/m2, a history of or current symptomatic CAD 
and a recent uncomplicated myocardial infarction without ST segment elevation. 
Participants were not excluded based on race/ethnicity or based on medications due to 
their necessity in this population. A list of current medications taken by our patient 
population can be found in Table 4.1. In this study, endurance-trained athletes were used 
as a model of optimal CAC function for comparison to the NSTEMI group. Endurance-
trained subjects were healthy, nonsmoking, men aged 18-39 yrs with no history of CV or 
metabolic disease. Potential subjects were initially screened by telephone or email, and 
reported to the laboratory following an overnight fast for a screening visit to verify 
eligibility. Subjects were categorized based on their reported physical activity over the 
last 5 years and confirmed via maximal oxygen consumption (VO2max) testing after 
achieving superior values according to the American College of Sports Medicine 
(ACSM) (107). Specifically, the endurance-trained group (n=13) reported performing >4 
hours/week of moderate to high intensity endurance exercise. Exclusion criteria for the 
athletes were as follows: systolic blood pressure ≥130 mm Hg, diastolic blood pressure 
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≥90 mm Hg, serum total cholesterol ≥200 mg/dl; low-density lipoprotein-cholesterol 
≥130 mg/dl; high-density lipoprotein-cholesterol ≤ 35 mg/dl; fasting glucose ≥100 mg/dl.  
Maximal Graded Exercise Test, Body Composition and Blood Sampling 
For the endurance-trained group, a screening blood sample was obtained for 
assessment of fasting serum triglyceride (TG), lipoprotein lipids, and glucose (Quest 
Diagnostics, Baltimore, MD). Height, weight, seated blood pressure and BMI were 
measured, and body composition was assessed using the 7-site skinfold procedure (62). 
VO2max was assessed using a constant-speed treadmill protocol with 2–3% increases in 
incline every 2 min until exhaustion. The treadmill speed was based on each subject’s 
experience, typical run speed, and heart rate, such that VO2max was achieved within 6–
12 min. Pulmonary ventilation and expired gas concentrations were analyzed in real time 
using an automated computerized indirect calorimetry system (Oxycon Pro, Viasys). VO2 
was considered maximum if a plateau was achieved (increase in VO2 of < 250 ml/min 
with increased work rate). In the absence of a clear plateau, tests had to meet at least two 
of the following secondary criteria: a respiratory exchange ratio > 1.10, a rating of 
perceived exertion >18, and a peak heart rate within 10 beats/min of the age-predicted 
maximum.  
On the testing day of blood sampling for CACs, the endurance-trained subjects 
reported to the laboratory in the morning after an overnight (~12 hr) fast. Subjects 
performed their normal exercise routine 16-24 hours prior to the blood sampling. A 
sample of 50mL of blood was drawn using EDTA-tubes (Becton Dickinson) for isolation 
of CD34-/CD31+ CACs and plasma. Blood sampling for the NSTEMI group was 
performed at the Baltimore Veterans Affairs Medical Center. Briefly, 50 mL blood 
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samples were obtained in EDTA-tubes between 24-72 hours after presentation to the 
emergency room, prior to cardiac catheterization procedures. Patients were NPO 
overnight prior to blood sampling. Samples were then immediately transported to the 
University of Maryland, College Park for processing. 
Immunomagnetic Cell Separation 
Peripheral blood mononuclear cells (PBMCs) were isolated from the venous 
blood samples using density gradient centrifugation (Ficoll, GE Healthcare). The CD34+ 
fraction was purified using multiple rounds of immunomagnetic cell separation according 
to the manufacturer’s instructions (EasySep® Immunomagnetic Cell Separation Kits, 
STEMCELL Technologies) using an antibody (Ab) specific for CD34. CD31+ cells were 
selected from the CD34- fraction of cells and purified as described above using and Ab 
specific for CD31 (hereby referred to as CD34-/CD31+). This isolation approach has 
been published previously by our lab (63, 64, 87) and the purity of our isolation is 
equivalent to or greater than other published results also using non-mobilized blood (3, 6, 
41, 128, 160).  
CAC Culture and Conditioned Media 
CD34-/CD31+ CACs were re-suspended in un-supplemented endothelial growth 
medium free of growth factors or serum, (EBM-2, Lonza) with 1% Antibiotic-
Antimycotic (Invitrogen) each at a density of 300,000 cells per well as determined by 
hemocytometer counts. Cultures were maintained for 48 hrs in a humidified incubator at 
37oC and 5% CO2. After incubation, the CM from all wells was withdrawn and combined 
into one tube and clarified by spinning at 2,500xg for 20 min to remove cells and debris 
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from the medium. CM not used for immediate experiments was flash frozen in small 
aliquots and stored at -80oC until further analyses. 
Angiogenesis Assay 
The angiogenesis tube formation assay (2, 19, 39, 125) was performed as done 
previously (87). Briefly, culture plates were coated with Reduced-Growth Factor 
Matrigel (BD Biosciences) and the matrigel was left to solidify for 30 min at 37oC and 
5% CO2. Each condition was performed in duplicate. Each well contained 20,000 
HUVECs and either endothelial basal medium (EBM-2) free of growth factors and serum 
or CM from CD34-/CD31+ CACs. For some conditions, HUVECs were pretreated with 
500nM TAK-242, a TLR4 inhibitor, 1µM FPS-ZM1, a RAGE antagonist, or both for 10 
minutes before exposure to CM. Concentrations of each drug treatment were determined 
through manufacturer recommendations as well as previous studies employing these 
drugs for treatment of HUVECs, and then further optimized in our laboratory. Additional 
wells were prepared with a similar amount of fresh EBM-2 as a positive control and 
DMSO vehicle controls. The average HUVEC passage used in the angiogenesis assay for 
endurance-trained and NSTEMI subjects were 4.1±0.4 and 4.2±0.3 respectively (n.s.). 
These plates were cultured for 16 hrs at 37oC and 5% CO2. The cultures were then 
visualized under a light microscope and 5 images were photographed from the center and 
periphery of each well. These images were then coded and assessed for HUVEC tube 
length, number of nodes, meshes and branches using the ImageJ Angiogenesis Analyzer 
software program. This program defines nodes as a connecting point between two 
branches, meshes as completely enclosed areas created by tube segments, and branches as 
tube segments sprouting from nodes but not forming complete meshes. Results are 
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presented as each condition normalized to the EBM-2 condition to control for daily 
variability in HUVEC growth and passage number within each assay.   
Mass Spectrometry, Western Blot Analysis and S100A8 and S100A9 Expression 
Proteomics techniques were used to determine proteins present in the CD34-
/CD31+ CM from the endurance-trained and NSTEMI groups. Spectral counts for n=3 
per group were used as an initial non-labeled method providing semi-quantitative data 
(99). Subsequently, these findings were quantitatively confirmed using immunoblotting 
analyses on n=10 per group. Media was concentrated using Amicon Ultra 0.5 3kD 
centrifugal filter devices (Millipore). The soluble proteins in the supernatant were 
subjected to digestion with trypsin Lys-C. Samples were analyzed using a 
ThermoFinnigan LTQ Orbitrap XL mass spectrometer and matched to the UniProtKB 
database. Western blot analyses were used to assess differences in two identified S100 
proteins with specific antibodies for S100A8 (R&D Systems) and S100A9 (Santa Cruz 
Biotech) as done previously (87). Membranes were washed and then incubated with 
horseradish peroxidase (HRP)-conjugated anti-mouse IgG (Cell Signaling; 1:1000) or 
HRP-conjugated anti-goat IgG (Novus; 1:5000) secondary antibodies. Blots were 
developed using Super Signal ECL reagents (Thermo Scientific) and bands were 
visualized and quantified using Chemi-Doc Imaging System and Software (BioRad). 
Values were normalized to the 300,000 cells/well used to generate the CM.  
Assessment of Gene Expression by RT-PCR 
Total RNA was extracted from freshly isolated CACs using the TriZol reagent, 
quantified using a spectrophotometer (BioTek H1 Synergy Hybrid Reader, Winooski, 
VT) and reverse transcribed to cDNA (Life Technologies, Grand Island, NY). 
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Quantitative real-time polymerase chain reaction (PCR) was performed using Applied 
BioSystems 7300 Real-Time PCR System. Primer Assays were purchased from IDT 
(Coralville, IA) and optimal concentration for efficacy of >90% was determined. Primer 
sequences are listed in Table 4.2. Each reaction was performed in duplicate on a 96-well 
plate and contained iTaq Universal Probes Supermix (Biorad, Hercules, CA), respective 
primer probe, and the cDNA template. The PCR conditions used were as follows: 95°C 
for 3 min, followed by 50 cycles of 95°C for 15 sec, and 60°C for 45 sec. mRNA 
expression values are presented as 2-ΔCT where ΔCT is the cycle threshold (CT) of the 
target gene minus GAPDH control for each condition. GAPDH primers were used as a 
control gene and GAPDH cycle thresholds (CTs) were not different across time in the 
present study. 
Recombinant S100A8 and S100A9 HUVEC treatment 
 To confirm the direct effects of S100A8 and S100A9 on HUVEC tube formation, 
the concentrations and proportions estimated in the CM of the athletes’ and NSTEMIs’ 
CD34-/CD31+ CACs were used in an angiogenesis assay. Using recombinant human 
S100A8/A9 (Life Technologies), a standard curve was established using immunoblotting 
to allow us to estimate the concentration of each protein that the HUVEC cells were 
exposed to in a subset of CM samples from each group (n=3/group). Based on these 
estimations, 2.9 µg/mL of recombinant human S100A8 (ProSpec Bio) and 0.8 µg/mL of 
recombinant human S100A9 (Life Technologies) were used to simulate the athlete 
conditions and 6.7 µg/mL of recombinant human S100A8 and 1.4 µg/mL of recombinant 
human S100A9 were used to match the NSTEMI conditions. These proteins were added 
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to a HUVEC-based tube formation assay and compared to the positive control prepared 
with EBM-2 and a vehicle control.  
In order to confirm the role of TLR4 in the inhibitory actions of these proteins on 
HUVECs, a condition in which the HUVECs were pretreated with 500nM TAK-242 
before exposure to NSTEMI concentrations of S100A8 and S100A9 was also included. 
In these experiments, each condition was assessed in samples collected from n=6 
independent cell culture wells from multiple culture plates collected on different days to 
confirm replication of our findings. All experiments were conducted on cells from the 
same passage number (P4). As described above, each well contained 20,000 HUVECs. 
The plates were cultured for 16 hrs at 37oC and 5% CO2. The cultures were then 
visualized under a light microscope and 5 random images were photographed per well. 
Signaling Experiments 
HUVECs were harvested and 180,000 cells/condition were used for experiments. 
HUVECs were exposed to either endothelial basal medium free of growth factors and 
serum or CM from CD34-/CD31+ CACs for 1 hour at 37oC and 5% CO2. For some 
conditions, HUVECs were pretreated with 500nM TAK-242, a TLR4 inhibitor, 1µM 
FPS-ZM1, a RAGE antagonist, or both for 10 minutes before exposure to CM. HUVECs 
were then spun at 1,000 x g for 5 min, supernatant was poured off and 1x Mueller buffer 
containing protease inhibitors was used to collect and lyse the cells. Cells were incubated 
at 4oC for 30 min in Mueller buffer while rotating, then spun down and the homogenate 
was collected in aliquots and stored at -80oC for future experiments. The average 
HUVEC passage used in signaling experiments for endurance-trained and NSTEMI 
subjects was 4.1±0.4 and 4.2±0.3 respectively (n.s.). For immunoblot analyses, samples 
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(n=6/group) were thawed and protein concentration was determined using a BCA protein 
assay (Thermo Scientific). Western blot analyses were used to assess differences in 
selected proteins involved in downstream signaling of TLR4 and RAGE using specific 
antibodies for p38 (phospho-p38 Thr180/Tyr182, 1:1000; total p38, 1:1000), ERK1/2  
(phospho-ERK1/2 Thr202/Tyr204, 1:2000; total ERK1/2, 1:1000), NFĸBp65 (phospho- 
NFĸBp65, 1:1000; total NFĸBp65, 1:1000) and IĸBα (1:1000). All antibodies were 
purchased from Cell Signaling. Membranes were washed and then incubated with HRP-
conjugated anti-mouse IgG or HRP-conjugated anti-rabbit IgG secondary antibodies 
(Cell Signaling; 1:1000). Blots were developed using Super Signal ECL reagents 
(Thermo Scientific) and bands were visualized and quantified using Chemi-Doc Imaging 
System and software (BioRad). The average basal condition from each membrane served 
as a blot control and values are presented as phospho/total target protein after 
normalizing to total protein, or normalized to total protein when no phosphorylation 
event was assessed. 
S100A8/A9 ELISA 
Plasma calprotectin (S100A8/A9 heterodimer complex) levels were measured 
using an enzyme-linked immunosorbant assay (ELISA) Kit (BMA Biomedical). This kit 
is designed to detect the heterodimer complex using a capture antibody that recognizes an 
epitope present on the heterodimer complex but that is not present on either of the 
monomers. The average intra-assay coefficient of variation was 6.9% and all samples 
were assayed on the same plate to avoid inter-assay variability. This assay has a 
sensitivity of ~1 ng/mL. 
Fluorescent Activated Cell Sorting 
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In an effort to further characterize these cells, flow cytometry was used to 
determine the percent of selected CD34-/31+ CACs that were also positive for the T-cell 
surface marker, CD3, macrophage surface marker, CD11b, and the monocyte surface 
marker, CD14. CD34-/31+ cells were isolated from total PBMCs using immunomagnetic 
isolation methods as described above. A total of 1x106 cells were FcR blocked (Miltenyi 
Biotech), immunostained with anti-human CD3-APC (BD Biosciences), CD11b-Pacific 
Blue (BD Biosciences), or CD14-PerCP (BD Biosciences), and fixed in 2% 
paraformaldehyde.  Flow cytometry analyses were performed in the University of 
Maryland Flow Cytometry Core Facility with a FACSCanto II flow cytometer (BD 
Biosciences). Data were analyzed with FlowJo software (FlowJo, LLC) using the 
appropriate isotype controls (BD Biosciences). 
Statistics 
Statistical analyses were completed using IBM SPSS Statistics 21. Assumptions 
of homoscedasticity and normality were verified for all outcome measures. Tube 
formation and HUVEC signaling data were analyzed using multivariate ANOVA with 
pairwise comparisons where appropriate. t-tests were used for western blot, ELISA and 
qPCR analyses. Statistical significance was accepted at P ≤ 0.05. Values are expressed as 
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RESULTS 
Subject characteristics 
Subject characteristics can be found in Table 4.3. VO2max assessments confirmed 
that the endurance-trained athletes were, by design, substantially above average in 
aerobic fitness for their age group according to American College of Sports Medicine 
Guidelines (107). Despite having suffered a recent cardiac event, NSTEMI patients were 
relatively lean with well-controlled blood pressure and plasma lipoprotein-lipid profiles. 
Angiogenic tube formation with conditioned media 
CM derived from NSTEMI patient CACs resulted in 9% lower total tube length 
(P<0.05; Figure 4.1A) and 18% fewer nodes (P=0.08; Figure 4.1B) compared to CM 
from endurance-trained athletes. Although the NSTEMI patients had a lower number of 
tube meshes and branches (Figure 4.1C and 4.1D), neither of these differences were 
significant compared to the endurance-trained athletes (P>0.05). Pre-treatment with 
TAK-242 significantly improved total tube length (P<0.05), number of branches 
(P<0.05), and number of meshes (P<0.05) in the NSTEMI patients compared to CM 
alone (Figure 4.1A-C). However, neither FPS-ZM1 treatment nor combined TAK-242 + 
FPS-ZM1 treatments significantly altered tube formation in the NSTEMI patients 
(P>0.05). There were significantly fewer branches in the NSTEMI group compared to the 
athletes when HUVECs were pretreated with FPS-ZM1 (P<0.05; Figure 4.1D). Drug 
treatments did not affect tube formation in the endurance-trained cell CM conditions 
(P>0.05). Representative images from each condition can be found in Figure 4.2. 
Detection of Proteins in Conditioned Media 
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In an attempt to compare secreted paracrine factors from CACs of athletes vs. 
NSTEMIs, CM from CD34-/CD31+ cells from each group were analyzed by mass 
spectrometry. A full list of identified proteins can be found in Supplemental table 4.I. As 
found previously, two targets from the S100 family of proteins, S100A8 and S100A9, 
were identified in the secretome of CD34-/CD31+ cells of both groups; with spectrum 
counts from S100A8 and S100A9 being 78% and 76% greater, respectively, in NSTEMIs 
compared to athletes (Figure 4.3A-B). Follow up immunoblotting (n=10/group) 
confirmed that there was 165% more S100A8 content in the CM from the NSTEMI 
group compared to the athletes (P<0.05; Figure 4.3C) and 153% greater S100A9 content 
in CD34-/CD31+ CM of NSTEMI subjects compared to endurance-trained athletes 
(P<0.05; Figure 4.3D). 
S100A8 and S100A9 Gene Expression 
qPCR analyses of CD34-/CD31+ CACs indicated that there was significantly 
greater expression of both S100A8 and S100A9 in the CACs of NSTEMIs compared to 
athletes (P<0.05 for both; Figure 4.4A-B).  
Recombinant human S100A8 and S100A8 treatment 
Recombinant human S100A8 (rhS100A8) and S100A9 (rhS100A9) were added to 
a HUVEC-based tube formation assay in the concentrations and proportions that were 
estimated to be present in the CD34-/CD31+ CM of endurance-trained athletes and 
NSTEMI patients. There were no significant differences observed between the basal 
condition and the condition using the concentrations of rhS100A8 and rhS100A9 
estimated to be present in the athlete CM. However, when using concentrations of each 
protein estimated to be present in the NSTEMI group CM, there was a 23% reduction in 
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tube length (Figure 4.5A; P<0.05), a 41% reduction in number of nodes (Figure 4.5B; 
P<0.05) and a 60% reduction in number of meshes (Figure 4.5C; P<0.05) compared to 
the basal condition. Importantly, this effect was rescued when the HUVECs were 
pretreated with TAK-242 before exposure to the recombinant proteins such that tube 
length, number of nodes, and number of meshes were significantly higher than basal and 
athlete conditions (Figure 4.5A-C; P<0.05). Number of tube branches was unchanged 
with any treatment (Figure 4.5D; P>0.05). Interestingly, only TAK-242 treatments also 
significantly improved tube length and number of nodes compared to basal and athlete 
conditions (data not shown; P<0.05). 
Assessment of Signaling Pathways 
No significant differences in phosphorylation of p38, ERK1/2 and NFκB p65 or 
degradation of IκBα were found between groups after a 1-hour exposure of HUVECs to 
CD34-/CD31+ CM (P<0.05; Figure 4.6). HUVEC pretreatment with TAK-242 prior to 
exposure to the CM from athletes resulted in higher phosphorylation levels of ERK1/2 
(P<0.05), p38 (P=0.06), and NFκB p65 (P<0.05) compared to the CM from NSTEMIs 
(Figure 4.6A-C). Additionally, within the athlete CM group, p- ERK1/2 was significantly 
higher with the TAK-242 treatment compared to all other conditions (P<0.05 for each; 
Figure 4.6A) and p-NFκB p65 was significantly higher with the TAK-242 treatment 
compared to basal, FPS-ZM1 and TAK242+FPS-ZM1 conditions (P<0.05 for each; 
Figure 4.6C). However, within the NSTEMI CM group, TAK-242 + FPS-ZM1 treatment 
combined lead to significantly higher p-ERK1/2 compared to basal and CM alone 
conditions (P<0.05 for both; Figure 4.6A), whereas this treatment resulted in lower p-
NFκB p65 compared to CM alone or FPS-ZM1 conditions (P<0.05 for both; Figure 
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4.6C). Additionally, within the NSTEMI CM group, TAK-242 treatment lead to 
significantly lower p-p38 compared to the basal condition (P<0.05; Figure 4.6B). There 
were no significant effects of group or treatment condition on IκBα (P>0.05; Figure 
4.6D). 
Plasma S100A8/A9 
No significant differences in plasma S100A8/A9 heterodimer complex were 
found between athletes and NSTEMIs (P>0.05; Figure 4.7). 
Characterization of CD34-/CD31+ CACs 
In an attempt to further characterize the selected CD34-/CD31+ CACs in athletes 
vs. NSTEMIs, we employed FACS analyses to identify percent of selected cells also 
positive for markers of angiogenic T-cells (CD3), macrophages (CD11b) and monocytes 
(CD14). Analyses of n=3/group indicates that in athletes, 42% more CD34-/CD31+ 
CACs were positive for CD3 and 56% more were positive for CD14 compared to 
NSTEMIs (n.s; Figure 4.8A-B). CD11b markers on CD34-/CD31+ cells were similar 
between groups (n.s.; Figure 4.8A-B). We followed up on these findings by looking at 
expression of angiogenic and inflammatory genes in CD34-/CD31+ CACs. There were 
no significant differences between groups in the angiogenic genes, angiopoietin-1, or 
FGF-2 (P>0.05 for both; Figure 4.9A-B). qPCR analyses of inflammatory genes 
indicated no significant differences between groups in TNF-α expression (P>0.05; Figure 
4.9C). However, expression of IL-1α was significantly higher in athletes compared to 
NSTEMIs (P<0.05; Figure 4.9D) 
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DISCUSSION 
It is generally accepted that CVD patients have fewer and lower functioning 
CACs compared to healthy adults (35, 76). Kim et al. (2014) recently demonstrated that 
selected CD31+ CACs from CAD patients exhibit lower functional properties compared 
to their healthy counterparts including adhesion, migration, and tube formation when co-
cultured with HUVECs (76). CD34-/31+ CACs function mainly through paracrine 
mechanisms to aid in the maintenance and repair of the endothelium, but how this 
function differs between CVD patient populations and optimally functioning healthy 
individuals is unknown. In this study we demonstrate for the first time that CM derived 
from CD34-/CD31+ CACs of NSTEMI patients impairs HUVEC tube formation 
compared to the CM from endurance exercise-trained individuals’ CACs. Our data 
provide further support for paracrine actions of CD34-/CD31+ CACs altering 
angiogenesis and how CVD might affect these actions.  
Previous work from our lab using similar methods to investigate the paracrine 
effects of CD34-/CD31+ CACs revealed a differential paracrine role of CD34-/CD31+ 
CACs on HUVEC-based tube formation as a function of chronic physical activity habits 
in otherwise healthy young individuals (87). We identified higher levels of S100A8 and 
S100A9 in the CM of inactive individuals compared to endurance-trained individuals and 
confirmed these proteins to be depressors of HUVEC tube formation (87). As a follow up 
to these findings, in the current study we sought to determine if S100A8 and S100A9 
were the major contributors to the observed lower tube formation when CD34-/CD31+ 
CM from NSTEMIs was used. Using mass spectrometry analyses on the CM from n=3 
from each group, we confirmed that spectrum counts for S100A8 and S100A9 were 
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higher in the NSTEMIs compared to the athletes. These findings were then supported 
through western blot analyses, which confirmed substantially greater levels of S100A8 
and S100A9 in the CM of the NSTEMIs compared to the athletes. Additionally, qPCR 
analyses confirmed that S100A8 and S100A9 mRNA expression was also substantially 
higher in the CD34-/CD31+ CACs of NSTEMIs compared to athletes. Collectively, these 
data indicate that the presence of CVD affects the expression and secretion of S100A8 
and S100A9 and provide additional support to our earlier study (87) suggesting that these 
proteins secreted by CD34-/CD31+ are playing a major role in the regulation of 
angiogenesis.  
In order to empirically test the effects of these proteins on HUVEC tube 
formation, we employed similar techniques as we had done previously (88) to estimate 
the concentrations of S100A8 and S100A9 that were present in the CD34-/CD31+ CM 
from NSTEMIs and athletes, which were then used in an angiogenesis assay. 
Concentrations of recombinant human S100A8 and S100A9 estimated to be present in 
the athletes’ CD34-/CD31+ CM did not significantly alter tube formation compared to 
the positive control. However, concentrations of S100A8 and S100A9 estimated to be 
present in the CM from NSTEMI patients’ CD34-/CD31+ CACs resulted in a ~23% 
lower tube length, ~41% fewer nodes, and ~60% fewer tube meshes compared to the 
positive control and the athlete conditions. These results support our hypothesis that 
S100A8 and S100A9 concentrations secreted by the CD34-/CD31+ CACs of the 
NSTEMIs contribute to the impaired angiogenic actions of these cells. Although 
S100A8/A9 plasma levels have been identified as risk factors for CVD (17, 43), this is 
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the first study, to our knowledge, to identify S100A8 and S100A9 secreted by NSTEMI 
patients’ CD34-/CD31+ CACs as a negative regulator of angiogenesis.  
Interestingly, isolating the effects of just S100A8 and S100A9 on HUVEC tube 
formation resulted in substantially larger reductions in tube formation than those 
observed when CM was used. It should be noted that proteomics analyses identified over 
250 proteins in the CM from the CD34-/CD31+ CACs. As this specific CAC subtype has 
known roles in angiogenesis, it is likely that other proteins present interacted with 
S100A8 and S100A9 to blunt their inhibitory actions or functioned separately to promote 
tube formation leading to an overall lesser observed effect than when the isolated effects 
of S100A8 and S100A9 are assessed. Thus, it is important that future studies explore 
potential interactions between S100A8/A9 and other secreted proteins to identify factors 
that may serve as endogenous inhibitors of these inflammatory proteins. 
To date, two major receptors for S100A8 and S100A9, RAGE and TLR4, have 
been identified on endothelial cells (26, 153, 155, 162). In this study, we demonstrate that 
inhibiting TLR4 signaling, but not RAGE, attenuated the negative actions of the 
NSTEMI patient’s CM on HUVEC tube formation. These results suggest that the major 
factor(s) present in the CM of NSTEMI patients’ CACs are acting primarily through 
TLR4. As TLR4 is a potential receptor for multiple proteins present in our CM, we 
sought to empirically test whether the inhibitory effects of the S100 proteins we observed 
were mediated by TLR4. Our results demonstrated that pretreating HUVECs with the 
TLR4 inhibitor before exposing them to recombinant human S100A8 and S100A9 in 
concentrations present in NSTEMI CD34-/CD31+ CM not only eliminated the 
attenuation in tube formation observed when HUVECs were exposed to S100A8 and 
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S100A9, but significantly improved tube formation compared to the positive control and 
the athlete condition. Interestingly, we also found that TAK-242 treatments alone 
significantly improved tube formation. TAK-242 acts by blocking TLR4 signaling of the 
intracellular domain (55). Some studies have found that this compound potentially 
suppresses ligand-independent signaling in addition to ligand-dependent signaling (73). 
TLR4-deficient mice have been found to exhibit impaired expression of pro-
inflammatory cytokines, which can promote angiogenesis (114). This potentially explains 
our observed improvements in tube formation in the TAK-242 control condition and 
suggests that TLR4 inhibition in itself is a possible method for improving angiogenesis. 
Follow-up studies investigating the roll of TLR4 and the use of the drug TAK-242 to 
inhibit TLR4 signaling are necessary. As a whole, our results indicate that S100A8 and 
S100A9 secreted by CD34-/CD31+ CACs from NSTEMI patients impair HUVEC tube 
formation and that these actions appear to be mediated by TLR4.  
In the current study we employed a gain of function experiment using 
recombinant S100A8 and S100A9 to mechanistically determine whether these proteins 
mediate the effects of the CM on tube formation. Future studies using 
immunoprecipitation, or other methods to block the function of S100A8 and S100A9 
from the CM, would not only further confirm our findings, but would also help to 
identify the extent to which the improvements in tube formation are mediated by S100A8 
and S100A9 ablation as opposed to suppression of TLR4 signaling. Similarly, small 
molecule inhibitors of TLR4 or other antibodies that exclusively block ligand-dependent 
signaling of TLR4 could be used to better understand the role of this receptor in 
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angiogenesis and the extent to which S100A8 and S100A9 are contributing to the 
reduced tube formation observed as a result of CD34-/CD31+ CM from NSTEMIs. 
Although S100A8, S100A9 and the S100A8/A9 heterodimer complex can each 
bind to TLR4, Wang et al. (2014) found that S100A8 preferentially binds to this receptor, 
with S100A9 having a preference for RAGE (162). Interestingly, when the 
concentrations of each of these proteins were estimated in the CM, there was 
proportionally more S100A8 present, suggesting the possibility that S100A8 is the major 
factor contributing to the observed negative effects on tube formation (118). S100A8 and 
S100A9 can function as monomers, as a heterodimer complex and as a heterotetramers 
with differences in their structure lending to functional diversity (153). Croce et al. 
(2009) demonstrated that the stability of these proteins is enhanced when functioning as a 
heterodimer complex (18), whereas several studies have experimentally tested the effects 
of each isolated protein (118, 162). Whereas methods to determine the physical structure 
of these proteins and their subsequent functions when secreted by CD34-/CD31+ CACs 
do not yet exist, future studies to test individual effects of S100A8 or S100A9 in the 
concentrations estimated to be present in the NSTEMI patients’ CD34-/CD31+ CM in 
cell culture experiments would provide more information as to whether one is playing a 
more predominant role in the negative regulation of angiogenesis. 
Upon binding to receptors present on endothelial cells, S100A8 and S100A9 are 
believed to modulate calcium signaling and cytoskeletal reorganization (18, 48, 153) 
through p38 and ERK1/2 signal pathways (162). One investigation into these signaling 
pathways in HUVEC cells found that S100A8/A9 caused endothelial barrier dysfunction 
increasing HUVEC monolayer permeability through RAGE and TLR4/p38/ERK1/2 
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signaling (162). As S100A8 and S100A9 are thought to be the predominant factors 
present in the CD34-/CD31+ CM that are affecting HUVEC tube formation, we sought to 
determine whether exposure to CD34-/CD31+ CM would activate similar signaling 
pathways in HUVECs and whether there would be differential response in NSTEMIs 
compared to athletes. We found that exposure to CD34-/CD31+ CM did not significantly 
alter p-ERK1/2, p-p38, p-NFκB p65 or IκBα in either group compared to the basal 
control. Additionally, we did not find any differences between groups with exposure to 
CD34-/CD31+ CM for any target protein. These results suggest that under our 
experimental conditions, factors within the CM for either group were not sufficient to 
activate these classically inflammatory signaling pathways.  
We did observe a differential response to the drug treatments between groups for 
several targets. However, our results collectively do not support our other findings. TAK-
242 treatments in the athlete group resulted in greater p-ERK1/2, p-p38 and p-NFκB p65 
compared the NSTEMI group. Additionally, in the presence of the athletes’ CD34-
/CD31+ CM, TAK-242 treatments resulted in greater p-ERK1/2, and p-NFκB p65 
compared to basal and CM only conditions. However, the same treatments used in the 
angiogenesis assay did not alter tube formation. Conversely, for the NSTEMI group, 
combined TAK-242 and FPS-ZM1 treatments resulted in greater p-ERK1/2 but reduced 
p-NFκB p65 compared to CM only conditions.  
As the signaling experiments included in this study are part of an exploratory aim, 
it is likely that several components remain to be worked out before these data can be used 
in conjunction with our other findings. For instance, the 1-hour exposure time to the 
CD34-/CD31+ CM was selected based on prior work demonstrating that these signaling 
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pathways reached peak activation after exposure to S100A8/A9 (162) for 1 hour, 
assuming that these proteins, if present in the CD34-/CD31+ CM, will result in peak 
signaling around the same timeframe. However, differences in the content of complete 
CD34-/CD31+ CM and isolated proteins may require a different timeframe for peak 
signaling in order to detect potential differences. Additionally, we were limited by the 
volume of CM we had to perform these experiments and as such, experiments were 
performed on a calculated number of harvested HUVECs, whereas other studies used 
cells in culture environments (162). Thus, differences in signaling and how drug 
treatments affect the HUVECs may exist in adherent vs. non-adherent cells. Cell 
signaling involves a series of complex actions. Consequently, in order to draw any 
concrete conclusions linking these signaling pathways to our observed results in tube 
formation, further work related to this aim is necessary.  
 Several studies have associated plasma S100A8/A9 with enhanced CV risk (5, 
17). Surprisingly, we did not find any significant differences in plasma S100A8/A9 
heterodimer complex between our endurance-trained subjects and NSTEMI patients. 
Most studies have examined plasma or serum S100A8/A9 concentrations as a predictor 
for CVD with few studies investigating systemic concentrations after an acute cardiac 
event (17, 43). Katashima et al. (2015) found that serum levels of S100A8/A9 peaked 3-5 
days after symptom onset of acute myocardial infarction in STEMI patients (71). Thus, it 
appears that the timing of blood sampling after an acute event is important for detecting 
alterations in systemic concentrations of the S100A8/A9 heterodimer complex. In our 
current study, samples were taken within 24-72 hrs days of symptom onset, potentially 
leading to variable results. 
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 A secondary aim of our study was to begin to characterize phenotypical traits of 
CD34-/CD31+ CACs from NSTEMI patients and endurance-trained group that may 
explain some of the observed differences in paracrine actions. Using a small subset of 
individuals from our study (n=3/group), we performed flow cytometry analyses and 
found that CD34-/CD31+ CACs from NSTEMI patients exhibited a lower percentage of 
markers for angiogenic T-cells (CD3) as well as monocytes (CD14) compared to the 
healthy endurance-trained athletes’ CD34-/CD31+ CACs. Kim et al. (2014) also found 
lower levels of CD3 present in CAD patients’ CD31+ CACs compared to healthy 
controls (76). However, contrary to our findings, they found higher levels of monocyte 
and macrophage markers in the CAD patients’ cells. They suggest that the higher 
presence of these markers may indicate that the CACs from CAD patients are involved in 
more of an inflammatory rather than angiogenic response. However, several studies have 
found that circulating cells positive for both monocyte and endothelial markers exhibit 
angiogenic behaviors (32, 132) and are recruited to sites of vascular injury and contribute 
to angiogenesis (77). In the present study, we did not note any differences between 
groups in the expression of two angiogenic genes of interest. However the CD34-/CD31+ 
CACs from athletes expressed higher IL-1α mRNA levels. IL-1α is typically known for 
its inflammatory role (76, 93), however there is also evidence for IL-1α promoting 
angiogenesis by stimulating secretion of vascular endothelial growth factor (VEGF) from 
circulating cells (127, 157). Thus, these findings, coupled with our other results suggest a 
more angiogenic phenotype in the CD34-/CD31+ CACs of athletes compared to 
NSTEMI patients.  
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The primary goal of this study was to determine if functional and mechanistic 
differences exist between two extreme populations – the young endurance-trained 
athletes and the older CVD patients; therefore, we did not include an older healthy 
control group in the study.  We know from our previous work, that differences in CD34-
/CD31+ CAC secretion of S100A8 and S100A9 exist as a function of habitual physical 
activity in younger healthy adults. However, the inclusion of a third group of healthy 
adults without CVD that were age-matched to the NSTEMIs would be a valuable 
addition in order to further understand how differences in these paracrine actions occur 
throughout the lifespan.  
Another limitation of this study is that the NSTEMI patients were currently taking 
a number of medications. Three athletes reported taking allergy or anxiety medications as 
needed and these medications were not taken for ≥ 12 hours prior to their tests and so 
likely did not affect any results. There are several medications that have been found to 
affect CAC number and function (28) and it is possible that some of the medications 
being taken by the NSTEMI patients affected our outcomes. We did not control for 
medications in the NSTEMI group because of the necessity of their habitual use in this 
population. Additionally, as our goal is to understand the function of CACs from patient 
populations that might benefit from autologous cell therapies, it is more physiologically 
relevant to study CACs from this group in the conditions at which they would be used if 
implementing these treatments.  
Conclusions 
In summary, we demonstrate, for the first time, that CD34-/CD31+ CM from 
NSTEMI patients impairs HUVEC tube formation and that these effects appear to be 
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mediated by TLR4. We found that pro-inflammatory S100A8 and S100A9 content were 
substantially higher in the CM from NSTEMI patients compared to athletes. Experiments 
using recombinant S100A8 and S100A9 in the concentrations estimated to be present in 
the NSTEMI’s CD34-CD31+ CM, but not the athlete’s CM, further confirmed that these 
proteins are major contributors to the impaired tube formation and that the observed 
effects appear to be mediated by TLR4. Methods designed to alter the production and 
secretion of S100A8 and S100A9 from CVD patients’ CD34-/CD31+ CACs to levels 
more similar to those of endurance-trained athlete’s CACs may improve the efficacy of 
treatments employing these cells for use in clinical populations. 
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Table 4.1. List of Medications 
Medication, n (%) NSTEMI Athlete 
Statin 7 (54) 0 
Blood Thinner 2 (15) 0 
ACE Inhibitor 4 (31) 0 
Beta Blocker 6 (46) 0 
Anti-diabetic 7 (54) 0 







Nitrate  2 (15) 0 
Prostaglandin E1 Agonist 1 (8) 0 
SSNRI 1 (8) 0 
Nonergot dopamine Agonist 1 (8) 0 
PDE5 Inhibitor 2 (15) 0 
Hypothyroidism 1 (8) 0 
Calcium channel blocker 3 (23) 0 
Diuretic 3 (23) 0 
Carbonic anhydrase inhibitor 1 (8) 0 
Ferrous Sulfate 2 (15) 0 
Other blood pressure medication 2 (15) 0 
Phosphate lowering medication 1 (8) 0 
Angiotensin 2 Receptor Blocker 2 (15) 0 
Antidepressant 2 (15) 2 (15) 
Anti-epileptic 2 (15) 0 










Table 4.2. RT-PCR genes and primer sequences 
Symbol                 Gene name Primer Sequence 
S100A8      S100 calcium binding protein A8     F: CCCATCTTTATCACCAGAATGAG 
   R: CCGAGTGTCCTCAGTATATCAG 
S100A9      S100 calcium binding protein A9     F: CCTCCATGATGTGTTCTATGACC 
   R: CAACACCTTCCACCAATACTCT 
ANGPT1    angiopoietin 1 
 
FGF-2        fibroblast growth factor-2 
 
IL1A           interleukin 1, alpha 
 
TNF            tumor necrosis factor, alpha 
   F: ACTTCCATCTTCACGATGTTGT 
   R: GACTGTGCAGATGTATATCAAGC 
   F: CTTCATAGCCAGGTAACGGTT 
   R: AGAAGAGCGACCCTCACA 
   F: TCTTCATCTTGGGCAGTCAC 
   R: GCTGCTGCATTACATAATCTGG 
   F: TCAGCTTGAGGGTTTGCTAC 
   R: TGCACTTTGGAGTGATCGG 
GAPDH      F: TGTAGTTGAGGTCAATGAAGGG 
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Table 4.3. Subject Characteristics 





Age (yr) 28±2 71±3* 
BMI (kg/m2) 22±0.6 26±1* 







SBP (mm Hg) 125±2.2 131±5 
DBP (mm Hg) 69±2.3 71±3 
MAP (mm Hg) 88±1.9 91±3 
Glucose (mg/dl) 79±2 113±2* 
Cholesterol (mg/dl) 172±9 169±18 
HDL-C (mg/dl) 69±5 44±3* 
LDL-C (mg/dl) 88±5 101±15 
VLDL-C (mg/dl) 15±4 - 
TC/HDL 2.5±0.2 3.8±0.4* 
LDL/HDL 1.3±0.2 2.2±0.3* 
Triglycerides (mg/dl) 55±6 118±24* 
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Figure 4.1. Quantification of HUVEC tube formation after culture with CM from 
CD34-/CD31+ CACs of endurance-trained athletes and NSTEMI patients with or 
without pretreatment of HUVECs with TAK242 (TLR4 signaling inhibitor) or FPS-
ZM1 (RAGE antagonist). CACs were cultured in un-supplemented endothelial growth 
medium free of growth factors or serum, each at a density of 300,000 cells per well of 
a fibronectin-coated plate. Media was collected after 48hrs of culture from each cell 
type. HUVEC tube formation was assessed using Image J angiogenesis analyzer to 
quantify total length in millimeters (mm) (A) number of nodes (B), number of meshes 
(C) and number of branches (D). Results are presented as each condition normalized 
to the basal (EBM-2) condition to control for daily variability in HUVEC growth and 
passage number with each assay. Images were taken under 5x magnification. * 
Indicates statistically significant difference from endurance-trained athletes. 
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Figure 4.2 
Figure 4.2. Representative images of HUVEC tube formation using CM from CD34-
/CD31+ CACs of endurance trained athletes and NSTEMI patients with and without 
HUVEC pretreatment with TAK242 (TLR4 signaling inhibitor) and/or FPS-ZM1 
(RAGE antagonist). 	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Figure 4.3 
Figure 4.3. Semi-quantitative analysis of S100A8 (A) and S100A9 (B) in CM of 
cultured CD34-/CD31+ cells using mass spectrometry spectrum counts (n=3/group) to 
identify proteins present in conditioned medium. Quantitative analyses using 
immunoblotting for secreted S100A8 (C) and S100A9 (D) protein content in cultured 
CD34-/CD31+ cell CM from endurance-trained athletes and NSTEMI patients (n=10 
per group). Values were normalized to cell number used to generate the CM (300,000 
cells/well) as equal volumes of CM were loaded for western blot analysis. 
Representative blots for CD34-/CD31+ CM (E). * Indicates statistically different from 
endurance-trained athletes. Significance accepted at P ≤ 0.05.	  
	  






































































Figure 4.4. (A) S100A8 and (B) S100A9 real-time mRNA expression for freshly 
isolated CD34-/CD31+ circulating angiogenic cells (n=10). GAPDH was used to 
normalize all data. * Indicates statistically significant at P<0.05. 
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Figure 4.5. Effects of recombinant human S100A8 and S100A9 in concentrations 
estimated to be present in the CM of CD34-/CD31+ CAC from athletes (2.9 µg/mL 
and 0.8 µg/mL, respectively), NSTEMI patients (6.7 µg/mL and 1.4 µg/mL, 
respectively) and NSTEMI patients after pretreatment of HUVECs with TAK-242 on 
tube formation compared to basal media and vehicle conditions. HUVEC tube 
formation was assessed using Image J angiogenesis analyzer to quantify total length in 
millimeters (mm) (A) number of nodes (B), number of meshes (C) and number of 
branches (D) and representative images from each condition (E). In these experiments, 
each condition was assessed in samples collected from six independent cell culture 
wells from multiple culture plates collected on different days. All experiments were 
conducted on cells from the same passage number (P4). * Indicates statistically 
different basal condition. # Indicates statistically different than rhS100 athlete 
condition. $ Indicates statistically different than vehicle condition. & Indicates 
statistically different than rhS10 NSTEMI condition. Significance accepted at P ≤ 
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Figure 4.6. Immunoblot analyses of HUVEC after 1 hr exposure to CM from athletes 
or NSTEMI CD34-/CD31+ CACs with or without pretreatment with TAK-242 or 
FPS-ZM1 (n=6/group). HUVECs were assessed for phosphorylation of (A) ERK1/2, 
(B) p38, and (C) NFκB p65 subunit or degradation of IκBα (D). The average basal 
condition from each membrane served as a blot control and values are presented as 
phospho/total target protein after normalizing to total protein, or normalized to total 
protein when no phosphorylation event was assessed. * Indicates statistically different 
from endurance-trained athletes. Significance accepted at P ≤ 0.05. 
	  

































Figure 4.7. Plasma S100A8/A9 heterodimer complex levels from fasting venous 
blood samples of endurance-trained athletes and NSTEMI patients (n=13/group). 
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Figure 4.8 
Figure 4.8. Characteristics of immunomagentically sorted CD34-/31+ CACs. A) 
Representative plots of athlete or NSTEMI CD34-/31+ CACs analyzed by flow 
cytometry for presence of CD3, CD11b and CD14. Blue area indicate isotype control 
and red areas indicate specific antibodies B) Mean percent positive CD3, CD11b and 
CD14 in athlete vs. NSTEMI selected CD34-/31+ CACs (n=3/group). 
	  




































































































Figure 4.9. (A) angiopoieten-1,  (B) FGF-2, (C) TNF-α and (D) IL-1α real-time 
mRNA expression for freshly isolated CD34-/CD31+ circulating angiogenic cells 
(n=10). GAPDH was used to normalize all data. * Indicates statistically significant at 
P<0.05. 
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Supplemental Table I. Proteins identified in the secretome of 
CD34-/31+ CACs by shotgun proteomics 
   
      





Average Number Total 
Spectra (n=3/group) 















kDa 33.7 56.0 









kDa 23.7 27.7 




kDa 31.7 37.0 














kDa 14.0 14.3 














kDa 6.0 9.0 









kDa 3.7 9.7 




kDa 4.7 10.7 
Lactotransferrin  
E7ER44_HU
MAN E7ER44  
78 
kDa 11.0 14.7 
















kDa 5.7 6.7 
Fibrinogen beta chain  
FIBB_HUM
AN P02675  
56 
kDa 12.0 13.7 









kDa 5.3 4.7 




kDa 10.7 15.3 




kDa 11.7 9.3 










kDa 2.7 5.7 




kDa 7.3 7.3 
Isoform 2 of Phosphoglycerate kinase 1  
PGK1_HUM
AN  P00558-2 
41 
kDa 4.7 5.7 




kDa 2.7 5.0 




kDa 7.3 6.0 









kDa 5.7 6.7 
SH3 domain-binding glutamic acid-rich-






kDa 5.7 5.0 









kDa 6.3 6.0 




141	   	  
binding protein 1  MAN kDa 




kDa 5.3 7.7 




kDa 4.3 5.3 
Histone H4  H4_HUMAN P62805 
11 
kDa 4.0 3.7 




kDa 1.7 3.3 




kDa 2.0 3.7 




kDa 3.3 4.0 














kDa 1.7 3.7 




kDa 5.3 5.7 
SH3 domain-binding glutamic acid-rich-




kDa 3.7 3.0 




kDa 9.0 8.3 




kDa 2.3 4.3 




kDa 4.7 5.3 











kDa 4.7 5.3 




kDa 4.3 4.0 




kDa 4.7 6.3 
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N  kDa 




kDa 5.0 6.0 




kDa 1.0 4.7 






kDa 4.7 4.7 
Serotransferrin TRFE_HUMAN P02787 
77 
kDa 4.0 5.3 




kDa 3.0 4.3 




kDa 2.0 4.3 




kDa 3.7 4.0 




kDa 3.7 4.0 
Heterogeneous nuclear 















kDa 2.7 3.0 




kDa 3.0 5.7 




kDa 5.0 6.3 




kDa 3.7 6.0 




kDa 4.0 3.7 






kDa 3.3 4.0 
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MAN kDa 




kDa 2.0 4.7 




kDa 4.7 3.7 










kDa 0.7 3.3 




kDa 1.3 3.0 
Glutathione S-transferase P GSTP1_HUMAN P09211 
23 
kDa 2.7 2.3 





kDa 3.3 3.0 




kDa 2.3 1.7 




kDa 3.3 2.7 




kDa 2.7 5.7 









kDa 2.0 4.3 




kDa 1.3 2.3 









kDa 0.7 4.0 





kDa 1.0 1.7 














144	   	  
CPPED1 MAN kDa 




kDa 2.0 2.3 




kDa 4.0 3.7 




kDa 2.0 3.0 




kDa 2.0 4.3 




kDa 2.3 2.3 










kDa 1.3 2.0 
Heterogeneous nuclear 











kDa 4.0 5.0 
Phosphatidylethanolamine-binding 




kDa 1.3 2.3 





kDa 1.0 2.7 







kDa 2.7 2.0 






kDa 1.0 0.7 




kDa 2.0 1.0 





kDa 0.7 1.7 









kDa 2.0 2.0 




kDa 0.0 1.0 
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AN kDa 




kDa 1.3 2.0 










kDa 2.0 1.0 










kDa 1.3 2.0 









kDa 0.3 2.0 




kDa 1.0 1.7 




kDa 1.0 1.3 
Lamina-associated polypeptide 2, 




kDa 0.7 0.7 




kDa 2.0 2.3 





kDa 3.7 2.7 




kDa 1.7 1.0 





kDa 0.0 1.3 




kDa 0.0 3.0 




kDa 0.7 1.3 




kDa 1.0 1.0 
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AN kDa 




kDa 0.7 2.3 





kDa 1.0 1.3 







kDa 2.3 1.7 
Apoptosis-associated speck-like protein 




kDa 0.0 1.0 











kDa 2.3 2.3 









kDa 1.3 4.0 




kDa 0.3 1.0 




kDa 1.3 2.7 




kDa 1.7 1.7 




kDa 1.7 5.0 






kDa 2.0 0.7 




kDa 3.7 1.3 




kDa 7.7 4.3 




kDa 0.7 1.0 




kDa 1.3 0.7 




kDa 0.7 1.3 
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MAN kDa 




kDa 0.7 0.7 






kDa 2.7 2.3 









kDa 0.7 1.3 
Immunoglobulin lambda-like 






kDa 1.0 1.3 



















kDa 1.0 1.7 









kDa 2.0 2.3 




kDa 0.3 1.0 









kDa 0.7 2.3 




kDa 1.7 1.0 




kDa 1.0 0.0 




kDa 0.3 0.7 






kDa 1.3 2.7 
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AN kDa 





kDa 1.0 1.0 




kDa 1.7 2.3 




kDa 1.0 0.7 




kDa 0.3 0.3 









kDa 0.3 0.3 




kDa 0.7 1.0 




kDa 1.0 1.7 




kDa 0.0 1.3 




kDa 0.3 1.0 
HLA class I histocompatibility antigen, 









kDa 1.0 0.7 




kDa 1.3 1.0 
Serine/threonine-protein phosphatase 6 









kDa 0.0 1.3 




kDa 1.0 0.7 




kDa 0.7 1.0 
Nuclease-sensitive element-binding 






kDa 1.0 1.0 
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subunit 2  MAN kDa 




kDa 2.3 2.3 




kDa 0.0 1.3 





kDa 0.3 1.0 




kDa 2.0 0.7 









kDa 1.0 1.3 
Microtubule-associated protein RP/EB 




kDa 0.3 1.3 
Rubber elongation factor protein HEVBR_HUMAN P15252 
15 
kDa 0.7 0.7 
26S proteasome non-ATPase regulatory 




kDa 0.3 0.7 
Isoform 4 of Tyrosine-protein 




kDa 0.0 0.7 




kDa 0.3 0.7 




kDa 0.7 1.0 




kDa 0.0 1.3 




kDa 0.3 0.7 





kDa 0.3 0.3 




kDa 2.3 0.3 




kDa 0.7 1.7 
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AN kDa 




kDa 1.3 3.7 





kDa 1.0 0.3 




kDa 0.3 0.3 




kDa 0.3 0.3 















kDa 0.0 0.3 




kDa 0.3 0.7 




kDa 0.3 0.3 




kDa 0.3 0.7 




kDa 2.0 1.7 




kDa 0.7 0.7 









kDa 0.7 0.3 
Phospholysine phosphohistidine 




kDa 0.7 0.0 




kDa 1.0 0.3 





kDa 0.7 0.3 
UV excision repair protein RAD23 




kDa 1.0 0.0 
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AN kDa 




kDa 0.0 1.0 









kDa 0.3 0.3 




kDa 1.0 0.7 




kDa 2.0 0.7 




kDa 0.7 1.0 





kDa 0.0 0.7 





kDa 0.0 0.7 




kDa 0.0 0.7 




kDa 0.7 1.0 





kDa 0.3 1.0 




kDa 1.3 0.7 
cDNA FLJ77421, highly similar to 




kDa 0.3 0.3 




kDa 0.7 1.0 




kDa 0.0 1.0 









kDa 0.0 0.7 




kDa 0.3 0.3 
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MAN kDa 










kDa 0.0 11.3 
LIM and senescent cell antigen-like-
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Chapter 5: Summary and Future Directions 
Summary 
 The studies presented in this dissertation provide new insight into differences in 
the paracrine actions of CACs as a function of habitual physical activity and CVD. 
Collectively, the two studies presented demonstrate that both physical inactivity and 
CVD alter the paracrine actions of CD34-/CD31+ CACs which in turn impair HUVEC 
tube formation. The first study presented identifies, for the first time, that secreted factors 
from CD34+ and CD34-/CD31+ CACs affect HUVEC tube formation as a function of 
habitual endurance-exercise with CM from inactive subjects CACs resulting in depressed 
tube formation compared to their active and endurance-trained counterparts. 
Additionally, study #1 identifies inflammatory proteins S100A8 and S100A9 as major 
factors contributing to the depressed tube formation observed when using CD34-/CD31+ 
CM inactive younger adults compared to endurance-trained athletes. 
The second study aimed to confirm the effects of S100A8 and S100A9 in CD34-
/CD31+ CM on HUVEC tube formation in CVD patient populations who would 
theoretically be candidates for autologous cell therapies using these same CACs and 
comparing these effects to endurance-trained athletes as a model of “optimal function”. 
Study #2 found that the CM from NSTEMI patient CD34-/CD31+ CACs impaired tube 
formation compared to athletes’ CM, and that pretreatment of HUVECs with an inhibitor 
for TLR4, a major receptor for S100A8 and S100A9, rescued tube formation to the levels 
observed when using CD34-/CD31+ CM from athletes. Additionally, this study found 
higher S100A8 and S100A9 content in the CM and higher mRNA expression of S100A8 
and S100A9 in the CD34-/CD31+ CACs. Finally, the study #2 mechanistically 
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demonstrated the direct role of S100A8 and S100A9 on tube formation when using 
recombinant S100A8 and S100A9 in concentrations present in NSTEMI patient CM, and 
confirmed that these actions were mediated by TLR4. Exploratory aims in study #2 did 
not indicate that CM from either group activated any of the signaling pathways 
downstream of TLR4. Preliminary data in study #2 suggest that cell surface markers on 
selected CD34-/CD31+ CACs are inherently different between NSTEMI patients and 
endurance-trained athletes with lower presence of T-cell and monocyte markers on the 
CD34-/CD31+ CACs of NSTEMI patients. These data paired with mRNA data suggest 
that the CD34-/CD31+ CACs from NSTEMI patients exhibit a less angiogenic phenotype 
compared to those from endurance-trained athletes, potentially explaining our observed 
differences in paracrine function. 
 Collectively, these studies indicate that the paracrine actions of CACs play a 
critical role in the cell’s ability to contribute to endothelial maintenance and repair. The 
inhibitory effects of CM as a function of physical inactivity or CVD on HUVEC tube 
formation that we observed in these studies may, at least in part, explain why autologous 
CAC therapies in to treat ischemic CVDs produce results that are inconsistent at best. 
These findings are of particular importance as new methods to improve CAC function for 
therapeutic purposes are being developed. Methods to suppress S100A8 and S100A9 
production and secretion from CD34-/CD31+ CACs of CVD patients so that they 
produce levels more similar to those found in endurance-trained athletes’ CACs may help 
to improve the efficacy of these autologous treatments in the future. 
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Limitations and Future Directions 
Although the studies presented in this dissertation provide a novel contribution to 
the literature regarding CAC paracrine function, there are several factors that should be 
considered for future investigations. One of the limitations of the final study is not 
including a healthy older group as a control. While the goal of our study was to compare 
the NSTEMI patients to what our lab has defined as a model of optimal CAC function, 
the inclusion of this third group would allow us to compare our findings to an age-
matched control group. Study #1 demonstrates that differences in CAC paracrine function 
exist even in younger, healthy adults as a function of endurance exercise training habits, 
but the degree to which changes in CAC paracrine function exist with aging are not yet 
known. Kim et al. (2014) explored various characteristics of CD31+ CACs in older 
healthy controls compared to CAD patients and found substantial differences in a number 
of phenotypical and functional characteristics, although paracrine function was not 
assessed (76). Thus, it would be interesting to determine how a similar older healthy 
population would compare to our young endurance-trained population and the NSTEMI 
patients. Additionally, although study #2 is the first, to our knowledge, to explore 
paracrine functions of CACs in NSTEMI patients, other CVD patient populations that 
may be candidates for autologous CAC treatments should also be explored in future 
studies to determine whether differences exist with chronic and acute CVDs. 
An exploratory aim of study #2 of this dissertation attempted to examine some of 
the signaling pathways within HUVECs downstream of TLR4 and RAGE in order to 
better understand how S100A8 and S100A9 present in the CD34-/CD31+ CM negatively 
influence HUVEC tube formation. Other studies have found that upon binding to their 
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receptor on endothelial cells, S100A8 and S100A9 cause cytoskeletal reorganization and 
increase endothelial permeability through MAPK signaling pathways (43, 162). Wang et 
al. demonstrated that S100A8, S100A9, and the S100A8/A9 heterodimer complex act 
through RAGE and TLR4 to activate p38 and ERK1/2 signaling pathways. There were 
several factors that limited our ability to fully explore these signaling pathways for this 
exploratory aim. The volume of CM that was available to perform these experiments was 
low and as such we were limited in the way the experiments were conducted. For this 
aim, exposure of HUVECs to the CM was performed on harvested HUVECs, rather than 
adherent cells as had been done in other studies (162). Future studies using adherent 
HUVECs would allow for more appropriate analyses since signaling is likely altered in 
suspended cells. Additionally, there was a low protein yield from the HUVECs after 
treatments took place. Protein assays indicated that the total protein present was on the 
low end of the standard curve (~5-10 µg/mL), and total protein gels performed indicated 
very low total protein loading. As such, it is likely that calculations estimating the 
volumes of each sample to load for immunoblot experiment were inaccurate leading to 
skewed results when probing for our target protein and high coefficients of variation for 
each target. Thus, an important future direction would be to further optimize the methods 
to best test this aim and to follow up on this research question. 
Inhibitors of p38 (SB203580) and ERK1/2 (PD98059) are also available (Sigma) 
and have been successfully used to study signaling mechanisms in HUVECs in other 
studies (162). Thus, there is potential for further experimentation with these signaling 
pathways in the future to gain more insight into the signaling mechanisms that are 
affecting HUVECs as a result of CM from CVD patients and endurance-trained subjects. 
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In addition to the intracellular signaling pathways of HUVECs upon exposure to 
CM from CD34-/CD31+ CACs, future studies should also focus on determining 
intracellular CAC functions that are potentially contributing to the increased production 
and secretion of S100A8 and S100A9 in NSTEMI patients compared to healthy controls. 
Study #1 of this dissertation investigated the role of intracellular ROS and NO as a 
function of habitual physical activity that might explain the differential paracrine effects. 
However, we found no differences between groups in either ROS or NO. Measurement of 
ROS and NO can be difficult due to a short half-life and a lack of globally accepted 
methods available to assess these functions. Thus, identification of better methods to 
assess these and other indicators of intracellular CAC signaling will help to better address 
this question. More information regarding intracellular function of CACs that are 
affecting paracrine actions will potentially allow for the development of new methods 
that can manipulate the production and secretion of particular factors to enhance the 
ability of CACs from CVD patients to be used for autologous therapies. 
In study #2 of this dissertation, we generated preliminary data using n=3/group to 
assess potential differences in cell surface markers that had been previously been shown 
to be differentially expressed in selected CD31+ CACs as a function of CVD (76). 
Although the sample size used for the analyses is study #2 was not large enough to detect 
significant differences, we did find that athletes CD34-/CD31+ CAC expressed nearly 
twice as much CD3 and CD14 compared to the NSTEMI cells. These preliminary 
findings suggest that despite selecting for CD34-/CD31+ in both groups, the selected 
cells are still inherently different with the presence of CVD and warrants follow-up work. 
Future studies should aim at further identifying potential differences in these cell surface 
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markers using a larger sample size as well as identifying other potentially different 
surface markers that may give further indication as to how these cells are functioning. 
The two studies presented in this dissertation employed the HUVEC-based tube 
formation assay to assess angiogenesis. This in vitro assay provides a global readout of 
the entire angiogenesis cascade but does not individually assess all the critical regulatory 
steps during angiogenesis. This assay was selected due to the ability to perform it on each 
individual day using fresh CM, since preliminary experiments using frozen CM indicate 
that there is degradation of many proteins and outcomes have not been successful thus 
far. Future studies should include measures such as HUVEC proliferation and migration 
as a complement to the angiogenesis assay to more comprehensively assess angiogenic 
activity in endothelial cells. Additionally, other assays that would allow for assessment of 
the effects of CM or S100A8 and S100A9 on endothelial function should also be 
considered for future investigations. 
 Generation of CM and preparation of CM samples between study #1 and study #2 
were further optimized such that we identified more than 250 proteins in the CD34-
/CD31+ CM in study #2. The focus of this dissertation work was on just S100A8 and 
S100A9 and although we have empirically shown that these proteins are significantly 
influencing HUVEC tube formation, we can not exclude the likelihood that other proteins 
present in the CM are both differentially expressed and contributing to the observed 
differences in tube formation as a function of physical inactivity and CVD. Indeed, 
proteomics results from study #2 investigating n=3 subjects per group indicate that there 
are multiple protein targets that are several fold different in the NSTEMIs compared to 
the athletes. Future investigations into these specific targets and the role(s) they play in 
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the regulation of angiogenic processes as well as the potential interplay between these 
proteins and S100A8/A9 would provide a more detailed picture as to how CD34-/CD31+ 
CAC paracrine function works. Additionally, due to our findings in study #1 indicating 
that S100A8 and S100A9 content in the CM of CD34-/CD31+ CACs was differentially 
expressed as a function of chronic endurance exercise habits, we did not follow up on the 
CD34+ CACs. However, we do have preliminary proteomics data on CM from both 
CD34+ and CD34-/CD31- CACs of NSTEMIs and endurance-trained athletes that can be 
used for future investigations. 
The likelihood that there are factors present in the CM aside from proteins that are 
potentially affecting tube formation should not be overlooked. Sahoo et al., found that 
exosomes were responsible for the paracrine effects of isolated CD34+ cells on 
angiogenesis and CM depleted of exosomes failed to create tube-like formations in vitro. 
Additionally, they found that microRNA-126 and microRNA-130a had known roles in 
promoting angiogenesis and were found in high concentrations in CD34+ CAC exosomes 
compared to total mononuclear cells (125). Exosomes are secreted bodies containing 
cytokines, mRNAs, microRNAs and other small particles. It is believed that exosomes 
help maintain stability of these factors as they are transported to and act on other cells. It 
is possible that some other factors being transported in exosomes, such as other proteins 
or microRNAs are being secreted in a differential manner or that the exosomes secreted 
by CVD patients’ CACs are dysfunctional causing early degradation of paracrine factors 
or inability of the exosomes to become internalized and act on HUVEC cells. We have a 
current collaboration with another lab in which they are quantifying the number and size 
of extracellular vesicles present in the CM of CD34-/CD31+ CACs. Additionally, these 
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extracellular vesicles have been isolated and we will be comparing the expression of 84 
CVD- related miRNA targets (Human Cardiovascular Disease miRNA PCRArray, 
Qiagen) in the CM of both athlete and NSTEMI patients’ CD34-/CD31+ CACs. These 
data will provide us with a number of potential avenues to follow up on to better ascertain 
the total effects of paracrine factors released by CD34-/CD31+ CACs and how they 
contribute to angiogenesis. Additionally, as we continue to identify paracrine factors that 
could be used for therapeutic purposes, it is our hope that this collaboration will help 
mold further investigations into the use of extracellular vesicles from CACs as a method 
for delivery of specific factors to promote repair of ischemic tissue. 
 
Together, the findings presented in this dissertation work, in addition to future 
directions presented above provide new understandings into the paracrine role of CACs 
and modulation of these actions by physical inactivity and CVD. Examination of the 
mechanisms affecting the paracrine function of CACs from individuals from different 
backgrounds is critical in order to better optimize the use of autologous CAC therapy to 
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